

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00615 A1(51) International Patent Classification⁷: C07D 401/14, A61K 31/4709, 31/4375, 31/437, 31/498, 31/4409, 31/436, A61P 11/00, 31/12, C07D 471/04, 417/14, 413/14, 409/14, 401/06, 491/056

(21) International Application Number: PCT/EP00/05677

(22) International Filing Date: 20 June 2000 (20.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 99202089.1 28 June 1999 (28.06.1999) EP

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LACRAMPE,


Jean, Fernand, Armand [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). GUILLEMONT, Jérôme, Emile, Georges [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). VENET, Marc, Gaston [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). ANDRIES, Koenraad, Jozef, Lodenwijk, Marcel [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department - 3547, Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS



(57) Abstract: The present invention concerns compounds of formula (I), prodrugs, N -oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein $\text{a}^1=\text{a}^2=\text{a}^3=\text{a}^4$ represents a radical of formula $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$; $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$; $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$; $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$; $-\text{CH}=\text{CH}-\text{CH}=\text{N}-$; wherein each hydrogen atom may optionally be substituted; Q is a radical of formulae (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), wherein Alk is $\text{C}_1\text{-}_6\text{alkanediyl}$; Y^1 is a bivalent radical of formula $-\text{NR}^2-$ or $-\text{CH}(\text{NR}^2\text{R}^4)-$; X^1 is NR^4 , S , $\text{S}(=\text{O})$, $\text{S}(=\text{O})_2$, O , CH_2 , $\text{C}(=\text{O})$, $\text{CH}=\text{CH}_2$, $\text{CH}(\text{OH})$, $\text{CH}(\text{CH}_3)$, $\text{CH}(\text{OCH}_3)$, $\text{CH}(\text{SCH}_3)$, $\text{CH}(\text{NR}^5\text{R}^6)$, $\text{CH}_2\text{-NR}^4$ or $\text{NR}^4\text{-CH}_2$; X^2 is a direct bond, CH_2 , $\text{C}(=\text{O})$, NR^4 , $\text{C}_1\text{-}_4\text{alkyl-NR}^4$, $\text{NR}^4\text{-C}_1\text{-}_4\text{alkyl}$, t is 2 to 5; u is 1 to 5; v is 2 or 3; and whereby each hydrogen in Alk and in (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), may optionally be replaced by R^3 ; provided that when R^3 is hydroxy or $\text{C}_1\text{-}_6\text{alkyloxy}$, then R^3 cannot replace a hydrogen atom in the α position relative to a nitrogen atom; G is a direct bond or optionally substituted $\text{C}_1\text{-}_10\text{alkanediyl}$; R^1 is an optionally substituted bicyclic heterocycle; R^2 is hydrogen, formyl, $\text{C}_1\text{-}_6\text{alkylcarbonyl}$, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, $\text{C}_3\text{-}_7\text{cycloalkyl}$ or $\text{C}_1\text{-}_10\text{alkyl}$ substituted with $\text{N}(\text{R}^6)_2$ and optionally with another substituent; R^3 is hydrogen, hydroxy, $\text{C}_1\text{-}_6\text{alkyl}$, $\text{C}_1\text{-}_6\text{alkyloxy}$, aryl $\text{C}_1\text{-}_6\text{alkyl}$ or aryl $\text{C}_1\text{-}_6\text{alkyloxy}$, R^4 is hydrogen, $\text{C}_1\text{-}_6\text{alkyl}$ or aryl $\text{C}_1\text{-}_6\text{alkyl}$; R^5a , R^5b , R^5c and R^5d are hydrogen or $\text{C}_1\text{-}_6\text{alkyl}$; or R^5a and R^5b , or R^5c and R^5d taken together from a bivalent radical of formula $-(\text{CH}_2)_s-$ wherein S is 4 or 5; R^6 is hydrogen, $\text{C}_1\text{-}_6\text{alkyl}$, formyl, hydroxy $\text{C}_1\text{-}_6\text{alkyl}$, $\text{C}_1\text{-}_6\text{alkylcarbonyl}$ or $\text{C}_1\text{-}_6\text{alkyloxycarbonyl}$; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.

WO 01/00615 A1

50



(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS

5 The present invention is concerned with benzimidazoles and imidazopyridines having antiviral activity, in particular, they have an inhibitory activity on the replication of the respiratory syncytial virus. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.

10 Human RSV or Respiratory Syncytial Virus is a large RNA virus, member of the family of Paramyxoviridae, subfamily pneumovirinae together with bovine RSV virus. Human RSV is responsible for a spectrum of respiratory tract diseases in people of all ages throughout the world. It is the major cause of lower respiratory tract illness during infancy and childhood. Over half of all infants encounter RSV in their first year of life,

15 and almost all within their first two years. The infection in young children can cause lung damage that persists for years and may contribute to chronic lung disease in later life (chronic wheezing, asthma). Older children and adults often suffer from a (bad) common cold upon RSV infection. In old age, susceptibility again increases, and RSV has been implicated in a number of outbreaks of pneumonia in the aged resulting in

20 significant mortality.

Infection with a virus from a given subgroup does not protect against a subsequent infection with an RSV isolate from the same subgroup in the following winter season. Re-infection with RSV is thus common, despite the existence of only two subtypes, A and B.


25 Today only three drugs have been approved for use against RSV infection. Ribavirin, a nucleoside analogue, provides an aerosol treatment for serious RSV infection in hospitalized children. The aerosol route of administration, the toxicity (risk of teratogenicity), the cost and the highly variable efficacy limit its use. The other two 30 drugs, RespiGam® and palivizumab, polyclonal and monoclonal antibody immunostimulants, are intended to be used in a preventive way.

35 Other attempts to develop a safe and effective RSV vaccine have all met with failure thus far. Inactivated vaccines failed to protect against disease, and in fact in some cases enhanced disease during subsequent infection. Live attenuated vaccines have been tried with limited success. Clearly there is a need for an efficacious non-toxic and easy to administer drug against RSV replication.


EP-A-0,005,318, EP-A-0,099,139, EP-A-0,145,037, EP-A-0,144,101,
 EP-A-0,151,826, EP-A-0,151,824, EP-A-0,232,937, EP-A-0,295,742, EP 0,297,661,
 EP-A-0,307,014, WO 92 01697 describe benzimidazole and imidazopyridine

5 substituted piperidine and piperazine derivatives as antihistaminics, antiallergics or serotonin antagonists.


Thus, the present invention concerns the compounds of formula (I)



10 their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein
 -a¹=a²=a³=a⁴ represents a bivalent radical of formula




15 wherein each hydrogen atom in the radicals (a-1), (a-2), (a-3), (a-4) and (a-5) may
 optionally be replaced by halo, C₁₋₆alkyl, nitro, amino, hydroxy,
 20 C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, carboxyl, aminoC₁₋₆alkyl, mono- or
 di(C₁₋₄alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl, or a
 radical of formula




25 wherein =Z is =O, =CH-C(=O)-NR^{5a}R^{5b}, =CH₂, =CH-C₁₋₆alkyl, =N-OH or
 =N-O-C₁₋₆alkyl;


Q is a radical of formula




-3-




(b-5)



(b-6)



(b-7)



(b-8)

wherein Alk is C₁₋₆alkanediyi;

Y¹ is a bivalent radical of formula -NR²- or -CH(NR²R⁴)-;

5

X¹ is NR⁴, S, S(=O), S(=O)₂, O, CH₂, C(=O), C(=CH₂), CH(OH), CH(CH₃),

CH(OCH₃), CH(SCH₃), CH(NR^{5a}R^{5b}), CH₂-NR⁴ or NR⁴-CH₂;

X² is a direct bond, CH₂, C(=O), NR⁴, C₁₋₄alkyl-NR⁴, NR⁴-C₁₋₄alkyl;

t is 2, 3, 4 or 5;


u is 1, 2, 3, 4 or 5;

v is 2 or 3; and


10 whereby each hydrogen atom in Alk and the carbocycles and the heterocycles defined in radicals (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8) may optionally be replaced by R³; with the proviso that when R³ is hydroxy or C₁₋₆alkyloxy, then R³ can not replace a hydrogen atom in the α position relative to a nitrogen atom;

15 G is a direct bond or C₁₋₁₀alkanediyi optionally substituted with one, two or three substituents selected from hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, C₁₋₆alkylthio, arylC₁₋₆alkylthio, arylcarbonyl, HO(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino and aryl;


20 R¹ is a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula




(c-1)




(c-2)




(c-3)




(c-4)




(c-5)



(c-6)



(c-7)



(c-8)

and said bicyclic heterocycles may optionally be substituted in either of the two cycles with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxy-C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono-or di(C₁₋₆alkyl)-amino, mono-or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{5c}-, aryl-SO₂-NR^{5c}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{5c}R^{5d}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono-or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-;

5 each n independently is 1, 2, 3 or 4;

10 each m independently is 1 or 2;

each p independently is 1 or 2;

each R² independently is hydrogen, formyl, C₁₋₆alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C₃₋₇cycloalkyl substituted with N(R⁶)₂, or C₁₋₁₀alkyl substituted with N(R⁶)₂ and optionally with a second, third or fourth

15 substituent selected from amino, hydroxy, C₃₋₇cycloalkyl, C₂₋₅alkanediyl, piperidinyl, mono-or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, aryl and aryloxy;

R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl or arylC₁₋₆alkyloxy;

R⁴ is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;

R^{5a}, R^{5b}, R^{5c} and R^{5d} each independently are hydrogen or C₁₋₆alkyl; or

20 R^{5a} and R^{5b}, or R^{5c} and R^{5d} taken together form a bivalent radical of formula -(CH₂)_s- wherein s is 4 or 5;

R⁶ is hydrogen, C₁₋₄alkyl, formyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl or C₁₋₆alkyloxycarbonyl;

aryl is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents

25 selected from halo, hydroxy, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, polyhaloC₁₋₆alkyl, and C₁₋₆alkyloxy;

Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.

30 The term prodrug as used throughout this text means the pharmacologically acceptable derivatives, e.g. esters and amides, such that the resulting biotransformation product of the derivative is the active drug as defined in the compounds of formula (I). The reference by Goodman and Gilman (The Pharmacological Basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p. 13-15) describing prodrugs generally, is hereby incorporated.

35

As used herein C₁₋₃alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as methyl, ethyl,

propyl, 1-methylethyl and the like; C_{1-4} alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the group defined for C_{1-3} alkyl and butyl and the like; C_{2-4} alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon

5 radicals having from 2 to 4 carbon atoms such as ethyl, propyl, 1-methylethyl, butyl and the like; C_{1-6} alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C_{1-4} alkyl and pentyl, hexyl, 2-methylbutyl and the like; C_{1-9} alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals

10 having from 1 to 9 carbon atoms such as the groups defined for C_{1-6} alkyl and heptyl, octyl, nonyl, 2-methylhexyl, 2-methylheptyl and the like; C_{1-10} alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C_{1-9} alkyl and decyl, 2-methylnonyl and the like. C_{3-7} cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C_{2-5} alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 2 to 5 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,5-pentanediyl and the like, C_{2-5} alkanediyl is substituted on C_{1-10} alkyl as provided for in the definition of R^2 , it is meant to be substituted on one carbon atom thus forming a spiro moiety; C_{1-4} alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl and the like; C_{1-6} alkanediyl is meant to include C_{1-4} alkanediyl and the higher homologues thereof having from 5 to 6 carbon atoms such as, for example, 1,5-pentanediyl, 1,6-hexanediyl and the like;

25 C_{1-10} alkanediyl is meant to include C_{1-6} alkanediyl and the higher homologues thereof having from 7 to 10 carbon atoms such as, for example, 1,7-heptanediyl, 1,8-octanediyl, 1,9-nonanediyl, 1,10-decanediyl and the like.

30 As used herein before, the term (=O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom. The term (=N-OH) forms a hydroxylimine moiety when attached to a carbon atom.

35 The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalo C_{1-6} alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C_{1-6} alkyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl. In case more than one halogen atoms are

attached to an alkyl group within the definition of polyhaloC₁₋₄alkyl, they may be the same or different.

5 As described hereinabove, R¹ defines a bicyclic heterocycle which may optionally be substituted. The substituents may be divided over both rings or they may be attached to one and the same ring.

10 When any variable (e.g. aryl, R², R³, R⁴, R^{5a}, R^{5b} etc.) occurs more than one time in any constituent, each definition is independent.

15 It will be appreciated that some of the compounds of formula (I) and their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

20 The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I), and their prodrugs, N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of 25 compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their prodrugs, N-oxides, salts, solvates or quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention. As used hereinafter the terms *trans* or *cis* are well-known by the person skilled in the art.

30 For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

35 The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically

acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic,

5 hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

10 Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic

15 and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

20 The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

25 The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be

30 used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl *p*-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.

35 It will be appreciated that the compounds of formula (I) may have metal binding, chelating, complexating properties and therefore may exist as metal complexes or metal chelates. Such metalated derivatives of the compounds of formula (I) are intended to be included within the scope of the present invention.

Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.


5

A special group of compounds are those compounds of formula (I) wherein one or more of the following restrictions apply:


- Q is a radical of formula (b-1), (b-3), (b-4), (b-5), (b-6), (b-7) or (b-8);

- X² is a direct bond, CH₂ or C(=O);


10 - R¹ is a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl, or a radical of formula




(c-1)




(c-2)




(c-3)




(c-4)




(c-5)



(c-6)



(c-7)



(c-8)

15 and said bicyclic heterocycles may optionally be substituted in either of the two cycles with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxy-C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)-amino, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, 20 C₁₋₆alkyl-SO₂-NR^{5c}-, aryl-SO₂-NR^{5c}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{5c}R^{5d}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono- or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-, each n independently is 1, 2, 3 or 4; each m independently is 1 or 2; each p independently is 1 or 2;

25 each R² independently is hydrogen, pyrrolidinyl, piperidinyl, homopiperidinyl, C₃₋₇cycloalkyl substituted with NHR⁶, or C₁₋₁₀alkyl substituted with NHR⁶ and optionally with a second, third or fourth substituent selected from amino, hydroxy,

C₃₋₇cycloalkyl, C₂₋₅alkanediyl, piperidinyl, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, aryl and aryloxy;
 - R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy or arylC₁₋₆alkyl;
 - R⁶ is hydrogen, C₁₋₄alkyl, formyl, C₁₋₆alkylcarbonyl or C₁₋₆alkyloxycarbonyl.

5

Another special group of compounds are those compounds wherein -a¹=a²-a³=a⁴- is a radical of formula (a-1), (a-2) or (a-3).

10 Yet another special group of compounds are those compounds wherein Q is a radical of formula (b-5) wherein v is 2, and Y¹ is -NR².

Also interesting compounds are those compounds wherein R² is C₁₋₁₀alkyl substituted with NHR⁶.

15 Other interesting compounds are those compounds wherein G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one two or three substituents selected from hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, HO(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n-.

20 Preferred compounds are :

(±)-N-[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-[1-(8-quinolinyloxyethyl)]-1*H*-benzimidazol-2-amine monohydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-bromo-5,6,7,8-tetrahydro-8-quinolinyloxy)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;

25 (±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinyloxy]-4-methyl-1*H*-benzimidazol-2-amine;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxalinyloxy)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(1-methyl-1*H*-benzimidazol-4-yl)methyl]-1*H*-benzimidazol-2-amine;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(ethoxy-8-quinolinylmethyl)-1*H*-benzimidazol-2-amine;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-(5,6,7,8-tetrahydro-5-quinoxalinyloxy)-1*H*-benzimidazol-2-amine;

30 (±)-N-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride trihydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride monohydrate;

(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(8-quinolinylmethyl)-1*H*-imidazo[4,5-c]pyridin-2-amine trihydrochloride dihydrate;
N-[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-amine;

5 *N*-[1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-yl]-1,3-propanediamine trihydrochloride monohydrate;
(\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine trihydrochloride dihydrate;
(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(8-quinolinylmethyl)-1*H*-imidazo[4,5-b]pyridine-2-amine trihydrochloride dihydrate;

10 (\pm)-*N*-[1-[1-(aminomethyl)-2-methylpropyl]-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine;
(\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine trihydrochloride trihydrate;

15 (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(1-isoquinolinylmethyl)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;
N-[1-(2-aminoethyl)-4-piperidinyl]-1-(5,6,7,8-tetrahydro-5-quinoxalinyl)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;
the prodrugs, the *N*-oxides, the addition salts, the quaternary amines, the metal complexes and the stereochemically isomeric forms thereof.

20

Most preferred compounds are :

(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine;

25 (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-amine;
(\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxalinyl)-4-methyl-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;
(\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(5,6,7,8-tetrahydro-2,3-dimethyl-5-quinoxalinyl)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate;

30 (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine;
(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxalinyl)-1*H*-benzimidazol-2-amine trihydrochloride monohydrate;

35 (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxalinyl)-4-methyl-1*H*-benzimidazol-2-amine trihydrochloride dihydrate;

(\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-4-methyl-1*H*-benzimidazol-2-amine monohydrate;

(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-c]pyridin-2-amine trihydrochloride tetrahydrate;


5 (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine;

(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-[(1-methyl-1*H*-benzimidazol-4-yl)methyl]-1*H*-benzimidazol-2-amine;

(\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-10 quinoxaliny)-4-methyl-1*H*-benzimidazol-2-amine;


the prodrugs, the *N*-oxides, the addition salts, the quaternary amines, the metal complexes and the stereochemically isomeric forms thereof.

In general, compounds of formula (I) can be prepared by reacting an intermediate of 15 formula (II-a) or (II-b), wherein P represents a protecting group, such as, for example C_1 alkyloxycarbonyl, or those protecting groups mentioned in Chapter 7 of 'Protective Groups in Organic Synthesis' by T Greene and P. Wuyts (John Wiley & Sons Inc., 1991), with an intermediate of formula (III), wherein W_1 is a suitable leaving group, such as a halo atom, e.g. chloro, bromo, in the presence of a suitable base, such as, e.g. 20 sodium hydride. Said reaction can be performed in a reaction-inert solvent, such as N,N -dimethylformamide.



Compounds of formula (I) wherein, in the definition of Q, R^2 or at least one R^6 25 substituent is hydrogen, said Q being represented by $H-Q_1$, and said compounds being represented by formula (I-a), can be prepared by deprotecting an intermediate of formula (IV) wherein P represents a protecting group, for example C_1 alkyloxycarbonyl, benzyl, or those protecting groups mentioned in Chapter 7 of

'Protective Groups in Organic Synthesis' by T Greene and P. Wuyts (John Wiley & Sons Inc., 1991).




5 When P represents, for example, C_{1-4} alkyloxycarbonyl, said deprotection reaction can be performed by, for example, acidic hydrolysis in the presence of a suitable acid, such as hydrobromic, hydrochloric, sulfuric, acetic, or trifluoroacetic acid or a mixture of said acids, or by alkaline hydrolysis in the presence of a suitable base, such as, for example potassium hydroxide, in a suitable solvent such as water, alcohol, a mixture of water-alcohol, methylene chloride. Suitable alcohols are methanol, ethanol,

10 2-propanol, 1-butanol and the like. In order to enhance the rate of the reaction, it is advantageous to heat the reaction mixture, in particular up to the reflux temperature. Alternatively, when P represents, for example, benzyl, the deprotection reaction can be performed by catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst in a reaction-inert solvent. A suitable catalyst in the above reaction is, for


15 example, platinum-on-charcoal, palladium-on-charcoal, and the like. An appropriate reaction-inert solvent for said reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like, an ester, e.g. ethylacetate and the like, an acid, e.g. acetic acid and the like.

20 The catalytic hydrogenation reaction described above can also be used to prepare a compound of formula (I-a) by deprotecting and reducing an intermediate of formula (IV) wherein Q_1 comprises an unsaturated bond, said Q_1 being represented by $Q_{1a}(CH=CH)$, and said intermediate being represented by formula (IV-a).



25 Compounds of formula (I) wherein, in the definition of Q, both R⁶ substituents are hydrogen or R² and R⁴ are both hydrogen, said Q being represented by H₂N-Q₂, and said compounds being represented by formula (I-a-1), can also be prepared by deprotecting an intermediate of formula (V).


-13-




Said deprotection reaction can be performed in the presence of a suitable base such as, for example hydrazine, or in the presence of a suitable acid, such as hydrochloric acid and the like, in a suitable solvent, such as an alcohol, acetic acid and the like.

5


Compounds of formula (I-a-1) can also be prepared by deprotecting an intermediate of formula (VI) according to the procedure described for the preparation of compounds of formula (I-a).



10 Compounds of formula (I-a) or (I-a-1), wherein Q₁ or Q₂ comprise a hydroxy substituent, said Q₁ or Q₂ being represented by Q₁·(OH) or Q₂·(OH), and said compounds being represented by formula (I-a-2) or (I-a-1-1), can be prepared by deprotecting an intermediate of formula (VII) or (VIII) as described hereinabove for the preparation of compounds of formula (I-a).




15



Compounds of formula (I) wherein, in the definition of Q, both R⁶ substituents are hydrogen or R² and R⁴ are both hydrogen, and the carbon adjacent to the nitrogen carrying the R⁶, or R² and R⁴ substituents contains at least one hydrogen, said Q being represented by H₂N-Q₃H, and said compounds being represented by formula (I-a-1-2)


5 can also be obtained by reductive amination of intermediates of formula (IX) in the presence of a suitable amination reagent, such as, for example, ammonia, hydroxylamine, or benzylamine, and in the presence of a suitable reducing agent, e.g. hydrogen, and an appropriate catalyst. An appropriate catalyst in the above reaction is, for example, platinum-on-charcoal, palladium-on-charcoal, rhodium-on-Al₂O₃, and the like, optionally in the presence of a catalyst poison, such as a thiophene solution. A suitable reaction-inert solvent for the above reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like.

10



Compounds of formula (I), wherein Q comprises a -CH₂NH₂ moiety, said Q being represented by H₂N-CH₂-Q₄, and said compounds being represented by formula (I-a-1-3) can be prepared by reducing an intermediate of formula (X).

15




Said reduction can be performed with a suitable reducing agent, such as lithium aluminium hydride or hydrogen, optionally in the presence of a suitable catalyst, such as Raney Nickel. A suitable solvent for the above reaction is, for example, tetrahydrofuran, or a solution of ammonia in an alcohol. Suitable alcohols are methanol, ethanol, 2-propanol and the like. Said reduction reaction performed in a solution of ammonia in an alcohol can also be used to prepare compounds of formula (I-a-1-3), wherein R¹ is substituted with C₁₋₆alkyloxyC₁₋₆alkyl, said R¹ being represented by R¹-C₁₋₆alkyloxyC₁₋₆alkyl, and said compounds being represented by formula (I-a-1-3-1) starting from an intermediate of formula (X-a).

20


25

-15-




Compounds of formula (I), wherein Q comprises a $-\text{CH}_2\text{CHOHCH}_2\text{NH}_2$ moiety, said Q being represented by $\text{H}_2\text{NCH}_2\text{CHOHCH}_2\text{Q}_4$, and said compounds being represented by formula (I-a-1-3-2), can be prepared by reacting an intermediate of formula (XI) with ammonia in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. methanol.

5 formula (XI) with ammonia in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. methanol.




Compounds of formula (I), wherein, in the definition of Q, R² or one R⁶ substituent is formyl, said Q being represented by H-C(=O)-O₁, and said compounds being

10 represented by formula (I-b), can be prepared by reacting an intermediate of formula (XII) with formic acid, formamide and ammonia.




15 Compounds of formula (I), wherein, in the definition of Q, R² is other than hydrogen, said R² being represented by R^{2a}, R⁴ is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the R² and R⁴ substituents, carries also at least one hydrogen atom, said Q being represented by R^{2a}-NH-HQ₅, and said compounds being represented by formula (I-c), can be prepared by reductive amination of an intermediate of formula (XIII) with an intermediate of formula (XIV) in the presence of a suitable reducing agent, such as hydrogen, and a suitable catalyst, such as palladium-on-charcoal,
20 platinum-on-charcoal, and the like. A suitable reaction-inert solvent for the above reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like.

-16-



Compounds of formula (I-c), wherein R^{2a} represents C_{1-10} alkyl substituted with $N(R^6)_2$ and with hydroxy, and the carbon atom carrying the hydroxy, carries also two hydrogen atoms, said R^{2a} being represented by $[(C_{1-9}\text{alkyl})CH_2OH]-N(R^6)_2$, and said compounds

5 being represented by formula (I-c-1), can be prepared by reducing an intermediate of formula (XV) in the presence of a suitable reducing agent, such as lithium aluminium hydride, in a suitable reaction-inert solvent, such as tetrahydrofuran.




Compounds of formula (I) wherein, in the definition of Q, R^2 or one R^6 substituent is 10 hydrogen, said Q being represented by $H-Q_1$, and wherein R^1 is a bicyclic heterocycle substituted with 1 or more substituents selected from hydroxy, hydroxy C_{1-6} alkyl, or $HO(-CH_2-CH_2-O)_n-$, said substituents being represented by formula $A-OH$, said R^1 being represented by $R^{1a}-(A-OH)_w$, with w being the amount of substituents on R^{1a} ranging from 1 to 4, and said compounds being represented by formula (I-d), can be


15 prepared by deprotecting an intermediate of formula (XVI) with a suitable acid, such as hydrochloric acid and the like, optionally in the presence of a suitable solvent, such as an alcohol. Suitable alcohols are methanol, ethanol, 2-propanol and the like.

Alternatively, one protecting group may also protect more than one substituent of R^{1a} , 20 said protecting group being represented by P_1 , as represented by formula (XVI-a). The two ways of protecting the substituents of R^{1a} , i.e. with a separate, as in formula (XVI), or a combined, as in formula (XVI-a), protecting group, may also be combined in the same intermediate, as represented by formula (XVI-b).

-17-




Compounds of formula (I), wherein Q is a radical of formula (b-2), said compounds being represented by formula (I-e), can be prepared by reacting an intermediate of formula (XVII) with an intermediate of formula (XVIII) in the presence of sodium cyanide and a suitable reaction-inert solvent, such as an alcohol, e.g. methanol and the like.




Compounds of formula (I), wherein in the definition of Q, X^2 is C_{2-4} alkyl-NR⁴, said Q being represented by $Q_6N-CH_2-C_{1-3}$ alkyl-NR⁴, and said compounds being represented by formula (I-p), can be prepared by reacting an intermediate of formula (XIX) with an intermediate of formula (XX) in the presence of isopropyl titanate (IV) and a suitable

reducing agent, such as NaBH_3CN , and in the presence of a suitable reaction-inert solvent, such as methylene chloride and an alcohol, e.g. ethanol.




5 Compounds of formula (I-p), wherein R^2 is C_{1-6} alkylcarbonyl, and Q is a radical of formula (b-6), wherein Y^1 is NR^2 , said compounds being represented by formula (I-p-1), can be prepared by reacting an intermediate of formula (XIX) with an intermediate of formula (XX-a) according to the procedure described for the preparation of a compound of formula (I-p).



10 Compounds of formula (I), wherein G is substituted with hydroxy or HO(-CH₂CH₂O)_n-, said G being represented by G₁-OH, and said compounds being represented by formula (I-q), may be prepared by deprotecting an intermediate of formula (XXI), wherein P represents a suitable protecting group, for example, benzyl. Said deprotection reaction can be performed by catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst in a reaction-inert solvent. A suitable catalyst in the above reaction is, for example, platinum-on-charcoal, palladium-on-charcoal, and the like. An appropriate reaction-inert solvent for said reaction is, for example, an alcohol, e.g. methanol, ethanol, 2-propanol and the like, an ester, e.g. ethylacetate and the like, an acid, e.g. acetic acid and the like.


15

-19-



Compounds of formula (I), wherein G is substituted with hydroxy and the carbon atom carrying the hydroxy substituent carries also at least one hydrogen, said G being represented by H-G₂-OH, and said compounds being represented by formula (I-q-1),

5 can also be prepared by reducing an intermediate of formula (XXII).




Said reduction reaction can be performed in the presence of a suitable reducing agent, such as, for example sodium borohydride, in a reaction-inert solvent, such as an alcohol or tetrahydrofuran or a mixture thereof. Suitable alcohols are methanol, ethanol,

10 2-propanol and the like.


Compounds of formula (I) may be converted into each other following art-known functional group transformation reactions, comprising those described hereinafter.

15 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise; for example, hydrogen peroxide, alkali metal or earth 20 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboper-oxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzene-carbo-peroxoic acid, peroxyoalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. 25 ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

Compounds of formula (I), wherein R^1 is a bicyclic heterocycle substituted with C_{1-6} alkyloxycarbonyl, said R^1 being represented by $R^{1'}-C(=O)OC_{1-6}$ alkyl, and said compounds being represented by formula (I-f), can be prepared by esterification of a compound of formula (I-g) in the presence of a suitable alcohol, e.g. methanol, ethanol, propanol, butanol, pentanol, hexanol and the like, and in the presence of a suitable acid, such as hydrochloric acid and the like.




Compounds of formula (I-a) may be converted into compounds of formula (I) wherein, in the definition of Q, R² or at least one R⁶ substituent is other than hydrogen, said R² or R⁶ being represented by Z₁, said Q being represented by Z₁-Q₁, and said compounds being represented by formula (I-h), by reaction with a reagent of formula (XXIII), wherein W₂ is a suitable leaving group, such as a halo atom, e.g. bromo, or 4-methylbenzenesulphonate, in the presence of a suitable base, such as, for example disodium carbonate, dipotassium carbonate, sodium hydroxide and the like, in a reaction-inert solvent, e.g. 3-methyl-2-butanone, acetonitrile, *N,N*-dimethylformamide.



Compounds of formula (I-h), wherein, in the definition of Z_1 , R^2 is $CH_2-C_{1-9}alkyl$ substituted with $N(R^6)_2$, said compounds being represented by formula (I-h-1), can also be prepared by reacting a compound of formula (I-a) wherein, in the definition of $H-Q_1$,

20 R^2 is hydrogen, said $H-Q_1$ being represented by $H-Q_{1b}$, and said compounds being represented by formula (I-a-3), with an intermediate of formula (XXIV), in the presence of a suitable reducing agent, such as sodium cyanoborohydride, in a suitable reaction-inert solvent, such as an alcohol.


-21-




Compounds of formula (I-h), wherein Z_1 comprises formyl, C_{1-6} alkylcarbonyl, Hetcarbonyl or C_{1-6} alkyloxycarbonyl, said Z_1 being represented by Z_{1a} , and said compounds being represented by formula (I-h-2), can be converted into compounds of

5 formula (I-a), by acidic hydrolysis in the presence of a suitable acid, such as hydrobromic, hydrochloric, sulfuric, acetic, or trifluoroacetic acid or a mixture of said acids, or by alkaline hydrolysis in the presence of a suitable base, such as, for example potassium hydroxide, in a suitable solvent such as water, alcohol, a mixture of water-alcohol, methylene chloride. Suitable alcohols are methanol, ethanol, 2-propanol,

10 1-butanol, sec. butanol and the like. In order to enhance the rate of the reaction, it is advantageous to work at elevated temperatures.




Compounds of formula (I-b) can be prepared by reacting a compound of formula (I-a) with formic acid.




15 Compounds of formula (I) wherein R^1 is a bicyclic heterocycle substituted with hydroxy, said R^1 being represented by $HO-R^{1'}$, and said compounds being represented by formula (I-i), can be prepared by deprotecting a compound of formula (I-j), wherein R^1 is a bicyclic heterocycle substituted with C_{1-6} alkyloxy or aryl C_{1-6} alkyloxy, said C_{1-6} alkyl or aryl C_{1-6} alkyl being represented by Z_2 , and said R^1 being represented by $Z_2-O-R^{1'}$. Said deprotection can be performed in a reaction-inert solvent, such as, for

-22-


example methylene chloride, in the presence of a suitable deprotecting agent, e.g. tribromoborane.




Compounds of formula (I) wherein R¹ is a bicyclic heterocycle substituted with
halo(-CH₂-CH₂-O)_n, said compounds being represented by formula (I-k), can be
converted into compounds of formula (I-l-1) or (I-l-2) by reaction with an appropriate
amine of formula (XXV) or (XXVI) in a suitable reaction-inert solvent, e.g.
tetrahydrofuran.



10 Compounds of formula (I) wherein R¹ is a bicyclic heterocycle substituted with halo, said compounds being represented by formula (I-m) can be converted into compounds of formula (I) by reaction with 1-butanethiol in the presence of palladium-on-charcoal and CaO in a suitable reaction-inert solvent, such as tetrahydrofuran.




Compounds of formula (I) wherein a hydrogen atom in the radicals of formula (a-1), (a-2), (a-3), (a-4) or (a-5) is replaced by nitro, said compounds being represented by formula (I-n) may be reduced to a compound of formula (I-o) in the presence of a suitable reducing agent, such as hydrogen, optionally in the presence of a suitable catalyst, such as platinum-on-charcoal, and optionally in the presence of a suitable catalyst poison, e.g. a thiophene solution. The reaction may be performed in a suitable reaction-inert solvent, such as an alcohol.



10 In the following paragraphs, there are described several methods of preparing the
intermediates in the foregoing preparations. A number of intermediates and starting
materials are commercially available or are known compounds which may be prepared
according to conventional reaction procedures generally known in the art or analogous
to the procedures described in EP-A-0005318, EP-A-0099139, EP-A-0151824,
EP-A-0151826, EP-A-0232937, EP-A-0295742, EP-A-0297661, EP-A-0539420,
15 EP-A-0539421, US 4,634,704, US 4,695,569.

In the foregoing and the following preparations, the reaction mixture is worked up following art-known methods and the reaction product is isolated and, if necessary, further purified.


20 Intermediates of formula (III) can be prepared by reacting an intermediate of formula (XXVII) with a suitable leaving group, i.e. W_1 , introducing agent, e.g. 1-halo-2,5-pyrrolidinedione in the presence of dibenzoyl peroxide, in a reaction-inert solvent, e.g. tetrachloromethane.




Intermediates of formula (XXVII), wherein R¹ is a bicyclic heterocycle substituted with chloro, said R¹ being represented by Cl-R¹ and said intermediates being represented by formula (XXVII-a) can be prepared by reacting an intermediate of formula (XXVIII).

-24-

wherein $(O=)R^{1b}H$ is defined as a carbonyl derivative of $R^{1'}$ wherein one carbon or nitrogen, adjacent to the carbonyl, carries at least one hydrogen, with phosphorus oxychloride. Intermediates of formula (XXVIII) may also react as their enol tautomeric forms.




Intermediates of formula (XXVII), wherein R¹ is 2-trifluoromethyl-3-methyl (3*H*)-imidazo[4,5-b]pyridine, and G is CH₂, said intermediates being represented by formula (XXVII-b), can be prepared by reacting N-2,6-dimethyl-2,3-pyridinediamine (Heterocycles, 38, p 529, 1994), with trifluoroacetic acid




Intermediates of formula (III) wherein W_1 is chloro, which is attached to a carbon atom carrying at least one hydrogen, said G being represented by G_3H , and said intermediates being represented by formula (III-a) can also be prepared by reacting an intermediate of formula (XXIX) with thionylchloride in a reaction-inert solvent, e.g.

15 methylenechloride.




Intermediates of formula (XXIX) can be prepared by reducing an intermediate of formula (XXX) in a reaction-inert solvent, e.g. an alcohol, in the presence of a suitable reducing agent, e.g. sodium borohydride.



Alternatively, intermediates of formula (XXIX) can also be prepared by deprotecting an intermediate of formula (XXXI), wherein P is a suitable protecting group, e.g. C₁₋₄alkylcarbonyl, in a reaction-inert solvent, such as an alcohol, in the presence of a suitable base, e.g. sodium hydroxide.

-25-




(XXXI)

(XXIX)

Intermediates of formula (XXX), wherein $G_3(=O)$ is $CH(=O)$, said intermediates being represented by formula (XXX-a), can be prepared by reacting an intermediate of formula (XXXII), wherein W_3 is a suitable leaving group, such as a halo atom, e.g.

5 bromo, with *N,N*-dimethylformamide in the presence of butyllithium in a reaction-inert solvent, e.g. tetrahydrofuran, diethylether or a mixture thereof.



(XXXII)

(XXX-a)


Intermediates of formula (XXX-a) can also be prepared by oxidizing an intermediate of formula $R^1\text{-CH}_2\text{-OH}$ in the presence of a suitable oxidizing agent, e.g. MnO_2 in a

10 reaction-inert solvent, e.g. methylenechloride.




Intermediates of formula $R^1\text{-CH}_2\text{-OH}$, wherein R^1 is 2,3-dimethylquinoxaline, said intermediates being represented by formula (XCI) can be prepared by reducing an intermediate of formula (XCI) in the presence of a reducing agent.

15 presence of a suitable reducing agent, e.g. potassium borohydride in the presence of lithium chloride.




Intermediates of formula (XCII) can be prepared by reacting ethyl 2,3-diaminobenzoate (Tetrahedron, 28, 3271, 1972) with 2,3-butanedione in the presence of disodium

20 disulfite.




-26-

Intermediates of formula (XXXI), wherein R¹ is 5,6,7,8-tetrahydroquinoline, which can optionally be substituted, G₃H is CH₂, and P is C₁₋₄alkylcarbonyl, said intermediates being represented by formula (XXXI-a) can be prepared by reacting an intermediate of formula (XCIII) with C₁₋₄alkylacid anhydride at elevated temperatures in the presence 5 of a suitable base, e.g. sodium hydroxide.




Intermediates of formula (XCIII) can be prepared by oxidizing an intermediate of formula (XCIV) with a suitable oxidizing agent, e.g. a peroxide such as 3-chlorobenzenecarboperoxoic acid, in a reaction-inert solvent, e.g. methylene chloride.

10




Intermediates of formula (XCIV) can be prepared by reducing an intermediate of formula (XCV) (Org. Prep. Proced. Int., 23, p 386-387, 1991) with an appropriate reducing agent, e.g. hydrogen, in the presence of a suitable catalyst, e.g. palladium-on-charcoal, and a suitable acid, e.g. trifluoroacetic acid.

15




Intermediates of formula (IV) can be prepared by reacting an intermediate of formula (XXXIII-a) or (XXXIII-b), wherein P represents a suitable protecting group, such as, for example, C₁₋₄alkyloxycarbonyl, with an intermediate of formula (III) according to the reaction described for the general preparation of compounds of formula (I).

-27-




Intermediates of formula (IV) can also be prepared by reacting an intermediate of formula (XXXIII-a) with an intermediate of formula (XXXIV) that has reacted with methanesulfonyl chloride, in the presence of a suitable base, such as sodium hydride, and in the presence of a suitable reaction-inert solvent, e.g. *N,N*-dimethylformamide.


5




Intermediates of formula (IV) can also be prepared by a cyclization reaction of an intermediate of formula (XXXV) in a reaction-inert solvent, e.g. an alcohol or *N,N*-dimethylformamide, in the presence of mercury oxide and sulphur.




Intermediates of formula (IV) wherein Q₁ comprises an unsaturated bond, said Q₁ being represented by Q_{1a}(CH=CH), and said intermediates by formula (IV-a), can be prepared by reacting an intermediate of formula (XXXVI) with an intermediate of formula (III) in the presence of a suitable base, such as dipotassium carbonate.



Intermediates of formula (IV) wherein, in the definition of Q_1 , the X^1 or X^2 moieties in the radicals of formula (b-1) to (b-8) represent NH, said Q_1 being represented by $Q_{1c}-NH$, and said intermediates by formula (IV-b), may also be prepared by reacting an intermediate of formula (XXXVII) with an intermediate of formula (XXXVIII).




Intermediates of formula (IV) wherein R^1 is a bicyclic heterocycle substituted with amino or mono- or di(C_{1-6} alkyl)amino, said R^1 being represented by $R^{5a}R^{5b}N-R^1'$, wherein R^{5a} and R^{5b} are defined as described above, and said intermediates being represented by formula (IV-c), can be prepared by reacting an intermediate of formula (XXXIX) with an appropriate amine, represented by formula (XL), in the presence of an appropriate catalyst, e.g. palladium, and (R)-(+)-2,2'-bis(diphenyl-phosphino)-1,1'-binaphthyl, in a suitable reaction-inert solvent, e.g. tetrahydrofuran.




Intermediates of formula (IV) wherein R^1 is a bicyclic heterocycle substituted with $C(=O)-NR^{5a}R^{5b}$, wherein R^{5a} and R^{5b} are defined as described above, said R^1 being represented by $R^{5a}R^{5b}N-C(=O)-R^1'$, and said intermediates being represented by formula (IV-d), can be prepared by reacting an intermediate of formula (XXXIX) with an appropriate amine, represented by formula (XL), under an atmosphere of carbon monoxide, in the presence of a suitable catalyst, e.g. palladium (II) acetate, and


1,3-bis(diphenylphosphino)propane, in a suitable reaction-inert solvent, e.g. tetrahydrofuran.



5 Intermediates of formula (IV) wherein P-Q₁ comprises C₁₋₁₀alkyl or C₃₋₇cycloalkyl substituted with NR⁶-P, said C₁₋₁₀alkyl or C₃₋₇cycloalkyl being represented by Z₃, said P-Q₁ being represented by P-NR⁶-Z₃-Q_{1b}, and said intermediates being represented by formula (IV-e), can be prepared by reacting a compound of formula (I-a-3) with an intermediate of formula (XLI), wherein W₄ represents a suitable leaving group, such as p-toluenesulphonate. Said reaction can be performed in a reaction-inert solvent, e.g. 10 acetonitrile, in the presence of a suitable base, e.g. dipotassium carbonate.




Intermediates of formula (IV-e), wherein R⁶ is hydroxyC₁₋₆alkyl, said intermediates being represented by formula (IV-e-1), can be prepared by reacting an intermediate of formula (XLII) with an intermediate of formula (XLIII) in the presence of a suitable base, e.g. dipotassium carbonate, and a suitable solvent, e.g. acetonitrile.



Intermediates of formula (XXXIII-a) or (XXXIII-b) can be prepared by protecting an intermediate of formula (XLIV) with a suitable protecting group, such as, for example, C_{1-4} alkyloxycarbonyl, in a reaction-inert solvent, such as methylene chloride or an alcohol, e.g. methanol, ethanol, 2-propanol and the like, in the presence of a suitable

-30-


reagent, e.g. di C₁₋₄alkyl dicarbonate and optionally in the presence of a suitable base, e.g. sodium acetate.



Alternatively, intermediates of formula (XXXIII-a) or (XXXIII-b) can be converted into an intermediate of formula (XLIV) by reaction with a suitable acid, such as hydrochloric acid or hydrobromic acid and the like or mixtures thereof, in the presence of a suitable solvent, e.g. water.



Intermediates of formula (XXXIII-a) or (XXXIII-b), wherein in the definition of Q₁, the X¹ or X² moieties in the radicals of formula (b-1) to (b-8) represent NH, said Q₁ being represented by Q_{1c}-NH, and said intermediates by formula (XXXIII-a-1) or (XXXIII-b-1), can be prepared by reacting an intermediate of formula (XLV-a) or (XLV-b), wherein W₅ represents a suitable leaving group, such as for example a halo atom, e.g. chloro, with an intermediate of formula (XLVI).

15





Intermediates of formula (XLV-a) or (XLV-b) can be prepared by reacting an intermediate of formula (XLVII-a) or (XLVII-b) with H₂P(=O)(W₅)₃ in the presence of a suitable acid, e.g. hydrochloric acid.


-31-



Intermediates of formula (XLVII-a) or (XLVII-b) can be prepared by reacting an intermediate of formula (XLVIII-a) or (XLVIII-b) with an intermediate of formula (IL).




5 Intermediates of formula (XXXIII-a) can also be prepared by reacting an intermediate of formula (XLVIII-a) with P-Q₁-C(=NH)-O-CH₂-CH₃ in a reaction-inert solvent, such as an alcohol.




10 Intermediates of formula (XXXV) can be prepared by reacting an intermediate of formula (L) with an intermediate of formula P-Q₁=C=S, which is synthesized according to the procedures described in EP 0005318, in a reaction-inert solvent, such as an alcohol, e.g. ethanol. To increase the reaction rate, the reaction may be performed at elevated temperatures.

-32-



Intermediates of formula (L) can be obtained by reducing an intermediate of formula (LI) in a reaction-inert solvent, e.g. an alcohol, in the presence of a suitable reducing agent, e.g. hydrogen, and an appropriate catalyst, e.g. Raney Nickel.


5



10


Intermediates of formula (LI) can be prepared by reacting an intermediate of formula (LII) with an intermediate of formula (LIII), in which W₆ represents a suitable leaving group, such as a halo atom, e.g. chloro. This reaction may be performed in a reaction-inert solvent, e.g. acetonitrile, in the presence of a suitable base, e.g. dipotassium carbonate.

10




Intermediates of formula (LII) can be prepared by reacting an intermediate of formula (LIV) with a suitable acid, such as hydrochloric acid, in the presence of a suitable solvent, e.g. an alcohol, e.g. ethanol.

15




Intermediates of formula (LIV) can be prepared by reacting an intermediate of formula (III) with NaN[C(=O)H]₂.


-33-




Intermediates of formula (LI) can also be prepared by reacting an intermediate of formula (LIII) with an intermediate of formula (LV) (J. Org. Chem., 25, p 1138, 1960) in a reaction-inert solvent, e.g. *N,N*-dimethylformamide, in the presence of an appropriate base, e.g. sodium hydride.



Intermediates of formula (XXXVI) can be prepared by dehydrating an intermediate of formula (LVI) with a suitable acid, such as sulfuric acid.




10 Intermediates of formula (LVI) wherein, in the definition of Q_{1a} , the X^1 or X^2 moieties are CH_2 , said Q_{1a} being represented by Q_{1a} , and said intermediates being represented by formula (LVI-a), can be prepared by reacting a carbonyl moiety of formula (LVII) with an intermediate of formula (LVIII) in the presence of *N,N*-diisopropylamine and butyl lithium, in a suitable reaction-inert solvent, e.g. tetrahydrofuran.




15 Intermediates of formula (IV), wherein G is C_{1-10} alkanediyl substituted with C_{1-6} alkyloxy, arylC_{1-6} alkyloxy, $\text{HO}(\text{---CH}_2\text{CH}_2\text{O})_n$, C_{1-6} alkyloxy($\text{---CH}_2\text{CH}_2\text{O})_n$, or arylC_{1-6} alkyloxy($\text{---CH}_2\text{CH}_2\text{O})_n$, said group of substituents being represented by O---Z_4 , said G being represented by $\text{Z}_4\text{---O---G}_1$, and said intermediates being represented by formula (IV-f), can be prepared by reacting an intermediate of formula (XXXIII-a), with an intermediate of formula (LIX), optionally in the presence of a suitable acid, such as *p*-toluenesulfonic acid and the like, and optionally in the presence of a suitable solvent,

such as *N,N*-dimethylacetamide. To increase the reaction rate, the reaction may be carried out at elevated temperatures.




Intermediates of formula (LIX) can be prepared by reacting an intermediate of formula 5 (LX) with a reagent of formula (LXI) or (LXII) in a reaction-inert solvent, such as an alcohol, or toluene, in the presence of an acid, e.g. 4-methylbenzenesulphonic acid.


Z_4-O-H (LXI) or



Intermediates of formula (LX) can be prepared by oxidizing an intermediate of formula 10 (LXIII) with a suitable oxidizing agent, e.g. MnO_2 , in a reaction-inert solvent, such as methylene chloride.




Intermediates of formula (IV-f) can also be prepared by reacting an intermediate of 15 formula (IV) wherein G is C_{1-10} alkanediyl substituted with hydroxy, said G being represented by G_1-OH , and said intermediates being represented by formula (IV-g), with an intermediate of formula (LXIV), wherein W_7 is a suitable leaving group, such as a halo atom, e.g. iodo, in the presence of a suitable base, e.g. sodium hydride, in a reaction-inert solvent, e.g. tetrahydrofuran.




Intermediates of formula (IV-g), wherein the carbon atom of G_1 carrying the hydroxy, 20 also carries a hydrogen atom, said G_1-OH being represented by $H-G_2-OH$, and said intermediates being represented by formula (IV-g-1), can be prepared by reducing an

intermediate of formula (LXV) in the presence of a suitable reducing agent, e.g. sodium borohydride, in a reaction-inert solvent, such as an alcohol, tetrahydrofuran or a mixture thereof. Intermediates of formula (LXV) can also first be deprotected, e.g. in the presence of a suitable acid, such as hydrochloric acid and the like, resulting in

5 intermediates of formula (LXVI), followed by a reduction, resulting in a compound of formula (I-q-1) wherein Q represents H-Q₁, said compounds being represented by formula (I-q-1-1).




10 Intermediates of formula (IV), wherein G is ethyl substituted with hydroxy, said intermediates being represented by formula (IV-g-2) can also be prepared by reacting an intermediate of formula (XXXIII-a) with an intermediate of formula (LXVII) in the presence of a suitable base, such as sodium hydride, in a reaction-inert solvent, such as *N,N*-dimethylformamide.




15 A subgroup of intermediates of formula (IV-g-2), represented by formula (IV-g-2-1), can also be prepared by reacting an intermediate of formula (LXVIII) with an

-36-


intermediate of formula (LXIX) in the presence of 1,3-dicyclohexylcarbodiimide, in a reaction-inert solvent, e.g. toluene.



Intermediates of formula (LXV) can be prepared by reacting an intermediate of formula (XXXIII-a) with an intermediate of formula (LXX), wherein W₈ is a suitable leaving group, such as a halo atom, e.g. bromo, in the presence of a suitable base, e.g. sodium hydride, in a reaction-inert solvent, e.g. *N,N*-dimethylformamide.




Intermediates of formula (V) can be prepared by reacting an intermediate of formula (LXXI) with 1*H*-isoindole-1,3 (2*H*)-dione in the presence of triphenylphosphine and diethyl azodicarboxylate.




Intermediates of formula (V) may also be prepared by reacting an intermediate of formula (LXXII) with 1*H*-isoindole-1,3 (2*H*)-dione in the presence of a suitable base, such as sodium hydride, and a suitable solvent, such as *N,N*-dimethylformamide.


-37-



Intermediates of formula (LXXII) can be prepared by reacting an intermediate of formula (LXXI) with an intermediate of formula (LXXIII), wherein W_9 represents a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, such as N,N -diethyl-ethanamine, and a suitable solvent, such as methylene chloride.




Intermediates of formula (V), wherein in the definition of Q_2 , R^2 is $C_{1-10}\text{alkyl}$, said Q_2 being represented by $C_{1-10}\text{alkyl}-Q_{1b}$, and said intermediates by formula (V-a), can be prepared by reacting a compound of formula (I-a-3) with an intermediate of formula (LXXIV), wherein W_{10} is a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, such as dipotassium carbonate, and a suitable solvent, such as acetonitrile.




Intermediates of formula (LXXI) wherein, in the definition of Q_2 , the carbon atom carrying the hydroxy, also carries two hydrogen atoms, said $HO-Q_2$ being represented by $HO-CH_2-Q_2$, and said intermediates being represented by formula (LXXI-a), can be prepared by reducing an intermediate of formula (LXXV) in the presence of a suitable reducing agent, such as lithium aluminium hydride, in a suitable reaction-inert solvent, e.g. tetrahydrofuran.

5 reducing agent, such as lithium aluminium hydride, in a suitable reaction-inert solvent, e.g. tetrahydrofuran.




Intermediates of formula (LXXI), wherein, in the definition of Q_2 , the carbon atom carrying the hydroxy, carries also at least one hydrogen atom, said $HO-Q_2$ being represented by $HO-Q_3H$, and said intermediates being represented by formula (LXXI-b), can be prepared by reducing an intermediate of formula (IX) with a suitable reducing agent, e.g. sodium borohydride, in a reaction-inert solvent, e.g. an alcohol.

10 reducing agent, such as sodium borohydride, in a reaction-inert solvent, e.g. an alcohol.




Intermediates of formula (VI) wherein, in the definition of Q_2 , R^2 is $C_{1-10}\text{alkyl}$ substituted with $N(P)_2$ and the carbon atom adjacent to the nitrogen atom carrying the R^2 substituent carries also at least one hydrogen atom, said Q_2 being represented by $(P)_2N-C_{1-10}\text{alkyl}-NH-Q_{2a}H$, and said intermediates being represented by formula (VI-a), can be prepared by reductive amination of an intermediate of formula (LXXVI) with an intermediate of formula (LXXVII) in the presence of a suitable reductive agent, such as 15 hydrogen, and a suitable catalyst, such as palladium-on-charcoal, platinum-on-charcoal, and the like, and optionally in the presence of a suitable catalyst poison, such as a thiophene solution. A suitable solvent in this reaction is a reaction-inert solvent, such as an alcohol.


20 as an alcohol.




Intermediates of formula (LXXVI) can be prepared by deprotecting an intermediate of formula (LXXVIII) in the presence of a suitable acid, such as hydrochloric acid and the like, in a suitable solvent, e.g. water.



Intermediates of formula (IX) may be prepared by deprotecting an intermediate of formula (LXXIX) in the presence of a suitable acid, e.g. hydrochloric acid and the like.




Intermediates of formula (LXXIX) can be prepared by reacting an intermediate of formula (LXXX) with an intermediate of formula (III) in the presence of a suitable base, e.g. dipotassium carbonate, in a suitable reaction-inert solvent, e.g. acetonitrile.




Intermediates of formula (LXXX) wherein, in the definition of Q₃, the X¹ or X² moiety of the radicals of formula (b-1) to (b-8) represent NH, said Q₃ being represented by Q₃-NH, and said intermediates being represented by formula (LXXX-a), may be prepared by cyclizing an intermediate of formula (LXXXI) in the presence of mercury oxide and sulphur, in a suitable reaction-inert solvent, e.g. an alcohol.

-40-




Intermediates of formula (LXXXI) can be prepared by reducing an intermediate of formula (LXXXII) in the presence of a suitable reducing agent, such as hydrogen, in the presence of a suitable catalyst, such as palladium-on-charcoal, platinum-on-charcoal

5 and the like, in a suitable solvent, e.g. a mixture of ammonia in alcohol. Suitable alcohols are methanol, ethanol, 2-propanol and the like.




Intermediates of formula (LXXXII) can be prepared by reacting an intermediate of formula (LXXXIII) with an intermediate of formula (LXXXIV) in a suitable reaction-

10 inert solvent, e.g. ethanol.




Intermediates of formula (IX), wherein, in the definition of Q₃, R² comprises C₁₋₁₀alkyl, said Q₃ being represented by C₁₋₁₀alkyl-Q_{1b}, and said intermediates being represented by formula (IX-a), can be prepared by reacting a compound of formula (I-a-3) with a

15 reagent of formula (LXXXV), wherein (O=)C₁₋₁₀alkyl represents a carbonyl derivative of C₁₋₁₀alkyl and wherein W₁₁ is a suitable leaving group, such as a halo atom, e.g. bromo, in a reaction-inert solvent, e.g. acetonitrile, in the presence of a suitable base, e.g. dipotassium carbonate.




Intermediates of formula (X) wherein Q₄ comprises C₁₋₉alkyl, said Q₄ being represented by C₁₋₉alkyl-Q_{1b}, and said intermediates being represented by formula (X-a), can be prepared by reacting a compound of formula (I-a-3) with a reagent of formula

5 (LXXXVI) wherein W_{12} represents a suitable leaving group, such as a halo atom, e.g. chloro, in a reaction-inert solvent, e.g. 3-methyl-2-butanone, in the presence of a suitable base, e.g. dipotassium carbonate, sodium bicarbonate and the like.




Intermediates of formula (X), wherein NC-Q₄ represents NC-(C₁₋₉alkyl)(R⁴)N-C(=O)-


10 Alk-X¹, said intermediates being represented by formula (X-b), can be prepared by reacting an intermediate of formula (LXXXVII) with an intermediate of formula (LXXXVIII) in the presence of di-1*H*-imidazol-2-yl-methanone, a suitable base, such as *N,N*-diethyl-ethanamine, and a suitable solvent, such as methylene chloride.



15 Intermediates of formula (XI), wherein Q_4 represents Q_{1b} , said intermediates being represented by formula (XI-a), can be prepared by reacting a compound of formula (I-a-3) with an intermediate of formula (LXXXIX), wherein W_{13} represents a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, such as disodium carbonate, and in the presence of a suitable solvent, such as 3-methyl-2-
20 butanone.



Intermediates of formula (XIX) can be prepared by reacting an intermediate of formula (XC) with a suitable acid, such as hydrochloric acid.



- 5 Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
- 10 The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- 15
- 20
- 25 The compounds of formula (I) show antiviral properties. Viral infections treatable using the compounds and methods of the present invention include those infections

brought on by ortho- and paramyxoviruses and in particular by human and bovine respiratory syncytial virus (RSV).

5 The *in vitro* antiviral activity against RSV of the present compounds was tested in a test as described in the experimental part of the description, and may also be demonstrated in a virus yield reduction assay. The *in vivo* antiviral activity against RSV of the present compounds may be demonstrated in a test model using cotton rats as described in Wyde et al. (Antiviral Research (1998), 38, 31-42).

10 Due to their antiviral properties, particularly their anti-RSV properties, the compounds of formula (I) or any subgroup thereof, their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms, are useful in the treatment of individuals experiencing a viral infection, particularly a RSV infection, and for the prophylaxis of these infections. In general, the compounds of the present

15 invention may be useful in the treatment of warm-blooded animals infected with viruses, in particular the respiratory syncytial virus.

20 The compounds of the present invention or any subgroup thereof may therefore be used as medicines. Said use as a medicine or method of treatment comprises the systemic administration to viral infected subjects or to subjects susceptible to viral infections of an amount effective to combat the conditions associated with the viral infection, in particular the RSV infection.

25 The present invention also relates to the use of the present compounds or any subgroup thereof in the manufacture of a medicament for the treatment or the prevention of viral infections, particularly RSV infection.

30 The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form or metal complex, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms

35 depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical

media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.

5 Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in

10 which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous

15 administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.

The compounds of the present invention may also be administered via oral inhalation or

20 insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the

25 administration of the present compounds.

Thus, the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier. Preferably, the compounds of the present invention are administered via inhalation of a solution in nebulized or

30 aerosolized doses.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated

tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

In general it is contemplated that an antivirally effective daily amount would be from

5 0.01 mg/kg to 500 mg/kg body weight, more preferably from 0.1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

10 The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is

15 well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.

20 Also, the combination of another antiviral agent and a compound of formula (I) can be used as a medicine. Thus, the present invention also relates to a product containing (a) a compound of formula (I), and (b) another antiviral compound, as a combined preparation for simultaneous, separate or sequential use in antiviral treatment. The

25 different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers. For instance, the compounds of the present invention may be combined with interferon-beta or tumor necrosis factor-alpha in order to treat or prevent RSV infections.

30 The following examples are intended to illustrate the present invention.

Experimental part

Hereinafter, "DMF" is defined as *N,N*-dimethylformamide, "DIPE" is defined as diisopropyl ether.

35 A. Preparation of the intermediate compounds

Example A1

a) Sodium methoxide (0.2 mol) was added to a mixture of *N*-(4-piperidinyl)-1*H*-benzimidazol-2-amine dihydrobromide (0.1 mol) in methanol (389ml), the mixture

was cooled on an ice bath and stirred for 2 hours.

Di-tert-butyldicarbonate (0.1mol) was added to a cooled mixture on an ice bath and then stirred for 18 hours at room temperature. The mixture was evaporated and suspended in water/DIPE. The residue was filtered off, washed with water/DIPE and dried. The residue was boiled up in CH₃OH, yielding 17.46g (55.2%) of 1,1-dimethylethyl 4-(1*H*-benzimidazol-2-ylamino)-1-piperidinecarboxylate; mp. 249.4°C (interm. 1).

5 b) A mixture of intermediate (1) (0.05 mol), 2-(chloromethyl)quinoline monohydrochloride (0.055 mol) and sodium carbonate (0.075 mol) in DMF (250ml) 10 was stirred at 55°C overnight. The solvent was evaporated. The residue was taken up in H₂O and CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3 and 95/5). The pure fractions were collected and the solvent was evaporated. The residue was suspended in DIPE, filtered off and dried, 15 yielding 13.5g (59%) of 1,1-dimethylethyl 4-[[1-(quinolinylmethyl)-1*H*-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 2).

Example A2

a) A mixture of 5,6,7,8-tetrahydro-2(1*H*)-quinoxalinone in phosphoryl chloride (200ml) was stirred and refluxed for 3 hours. The solvent was evaporated. The 20 residue was taken up in ice and CH₂Cl₂. The mixture was basified with NH₄OH. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated, yielding 34g (86%) of 2-chloro-5,6,7,8-tetrahydroquinoxaline (interm. 3).

b) A mixture of intermediate (3), 1-bromo-2,5-pyrolidinedione (0.116 mol) and dibenzoyl peroxide (1.3g) in tetrachloromethane (400ml) was stirred and refluxed for 25 35 minutes, brought to room temperature and then filtered. The reaction was carried out again using the same quantities. The residues were combined. The solvent was evaporated. The residue (60g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/5; 15-35 µm). Two pure fractions were collected and their solvents were evaporated, yielding 25 g (43%) of (±)-5-bromo-2-chloro-5,6,7,8- 30 tetrahydroquinoxaline (interm. 4) and 12 g (21%) of (±)-8-bromo-2-chloro-5,6,7,8-tetrahydroquinoxaline.

c) A dispersion of sodium hydride in mineral oil (60%) (0.0518 mol) was added portionwise at 5°C under N₂ flow to a mixture of intermediate (1) (0.0471 mol) in DMF (200ml). The mixture was stirred at 5°C/10°C for 1 hour. A solution of 35 intermediate (4) (0.0565 mol) in DMF (50ml) was added dropwise. The mixture was stirred at room temperature for 3 hours and poured out into H₂O. The precipitate was

filtered off and taken up in CH_2Cl_2 . The organic solution was dried (MgSO_4), filtered and the solvent was evaporated. The residue (32g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.1; 20-45 μm). The pure fractions were collected and the solvent was evaporated, yielding 13.3g (58%) of (\pm)-1,1-dimethylethyl 4-[[1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxalinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 5).

Example A3

- a) 2,3-Butanedione (0.0776 mol) was added at room temperature to a solution of sodium pyrosulfite (0.1 mol) in water (75ml). The mixture was heated to 70°C and then added to a solution of ethyl 2,3-diaminobenzoate (0.0776 mol) in water (75ml). The mixture was stirred at 100°C for 12 hours, cooled, basified with K_2CO_3 10% and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (17.5g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ 93/7; 20-45 μm). The pure fractions were collected and the solvent was evaporated, yielding 12g (67%) of ethyl 2,3-dimethyl-5-quinoxalinecarboxylate (interm. 6).
- b) Lithium chloride (0.6 mol) was added portionwise at 80°C to a mixture of intermediate (6) (0.06 mol) and potassium tetrahydroborate (0.6 mol) in tetrahydrofuran (300ml). The mixture was stirred at 80°C for 5 hours, cooled, poured out into H_2O and extracted with EtOAc. The organic layer was separated, washed with H_2O , dried (MgSO_4), filtered and the solvent was evaporated, yielding 10.5g (91%) of (\pm)-1,2,3,4-tetrahydro-2,3-dimethyl-5-quinoxaline-methanol (interm. 7).
- c) MnO_2 (100g) was added portionwise at room temperature to a mixture of intermediate (7) (0.0546 mol) in dichloromethane (500ml). The mixture was stirred at room temperature overnight, filtered over celite, washed with CH_2Cl_2 and the filtrate was evaporated. The product was used without further purification, yielding 7.8g (77%) of 2,3-dimethyl-5-quinoxalinecarboxaldehyde (interm. 8).
- d) Sodium tetrahydroborate (0.084 mol) was added portionwise at 5°C to a mixture of intermediate (8) (0.042 mol) in methanol (100ml). The mixture was stirred at 5°C for 30 minutes, hydrolized cold and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated, yielding 6.7g (85%) 2,3-dimethyl-5-quinoxalinemethanol (interm. 9).
- e) Thionyl chloride (0.045 mol) was added dropwise at 5°C to a mixture of intermediate (9) (0.03 mol) in dichloromethane (50ml). The mixture was stirred at room temperature for 2 hours, poured out on ice and K_2CO_3 10%. The organic layer was separated, washed with K_2CO_3 10%, dried (MgSO_4), filtered and the solvent was

evaporated. The product was used without further purification, yielding 6.2g (quant.) of 5-(chloromethyl)-2,3-dimethyl-quinoxaline (interm. 10).

f) A dispersion of sodium hydride in mineral oil (60%) (0.021 mol) was added

portionwise at 5°C under N₂ flow to a mixture of intermediate (1) (0.02 mol) in DMF

5 (30ml). The mixture was stirred at 5°C under N₂ flow for 1 hour. A solution of intermediate (10) (0.03 mol) in a small amount of DMF was added dropwise at 5°C. The mixture was stirred at room temperature under N₂ flow for 2 hours, hydrolyzed and extracted with EtOAc. The organic layer was separated, washed several times with H₂O, dried (MgSO₄), filtered and the solvent was evaporated. The residue (12.5g) was 10 purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97.5/2.5/0.1; 20-45 µm). Two pure fractions were collected and their solvents were evaporated, yielding 7.8g (80%) of 1,1-dimethylethyl 4-[[1-[(2,3-dimethyl-5-quinoxaliny) methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 11).

Example A4

15 8-Bromo-2-methylquinoline (0.0675 mol) was added portionwise at -70°C under N₂ flow to a mixture of a solution of butyllithium in hexane (1.6M) (0.135 mol) in tetrahydrofuran (300ml) and diethyl ether (300ml). The mixture was stirred for 30 minutes. A solution of DMF (0.405 mol) in tetrahydrofuran (100ml) was added quickly. The mixture was cooled to -70°C and stirred for 15 minutes. Ethanol (70ml) 20 and a NH₄Cl solution 10% were added. The mixture was brought to room temperature and stirred for 15 minutes. NH₄Cl was added. The mixture was extracted with EtOAc. The organic layer was separated, washed with H₂O, dried (MgSO₄), filtered and the solvent was evaporated. The product was used without further purification, yielding 15g (>100%) of 2-methyl-8-quinolinecarboxaldehyde (interm. 12).

25 Example A5

a) A mixture of 3-methoxy-2-methylquinoline (0.081 mol) in trifluoro-acetic acid (150ml) was hydrogenated at room temperature under a 3-4 bar pressure for 48 hours with palladium on activated carbon (2g) as a catalyst. After uptake of hydrogen (2 equiv.), the catalyst was filtered through celite and washed with H₂O. The filtrate

30 was basified with a concentrated NH₄OH solution and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated, yielding 14.3g (quant.) of 5,6,7,8-tetrahydro-3-methoxy-2-methylquinoline (interm. 13).

b) 3-Chlorobenzenecarboxylic acid (0.1 mol) was added portionwise at 5°C to a mixture of intermediate (13) (0.067 mol) in dichloromethane (300ml). The mixture

35 was stirred at room temperature overnight, basified with K₂CO₃ 10% and separated into its layers. The aqueous layer was extracted with CH₂Cl₂. The combined organic

layer was dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 13.7g (quant.) of 5,6,7,8-tetrahydro-3-methoxy-2-methylquinoline, 1-oxide (interm. 14).

c) A mixture of intermediate (14) (0.067 mol) in acetic anhydride (100ml) was stirred at 90°C for 1 hour, poured out on ice and basified with NaOH 3N. CH_2Cl_2 was added.

5 The organic layer was separated, washed with a diluted NaOH solution, dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 16.8g (quant.) of 5,6,7,8-tetrahydro-3-methoxy-2-quinolinemethanol acetate (ester) (interm. 15).

d) A mixture of intermediate (15) (0.067 mol) and sodium hydroxide (13g) in methanol (60ml) was stirred and refluxed for 20 minutes, poured out on ice and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated, yielding 12.3g (95%) of 5,6,7,8-tetrahydro-3-methoxy-2-quinolinemethanol (interm. 16).

In a similar way was also prepared (\pm)-5,6,7,8-tetrahydro-2-methyl-8-quinolinol (interm. 17).

15 Example A6

Phosphorus tribromide (0.0105 mol) was added dropwise at 0°C/5°C under N_2 flow to a mixture of (\pm)-5,6,7,8-tetrahydro-2-methyl-8-quinolinol (intermediate 17) (0.03 mol) in toluene (20ml). The mixture was brought to room temperature and stirred at room temperature overnight. Ice water was added. The mixture was basified with a

20 concentrated NaOH solution and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (6g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2/CH_3OH 99/1; 20-45 μ m). The pure fractions were collected and the solvent was evaporated, yielding 2g (29%) of (\pm)-8-bromo-5,6,7,8-tetrahydro-2-methylquinoline (interm. 18).

25 Example A7

a) A mixture of *N*-2,6-dimethyl-2,3-pyridinediamine (0.122 mol) in trifluoro-acetic acid (250ml) was stirred and refluxed for 6 hours and brought to room temperature. The solvent was evaporated. The residue was taken up in CH_2Cl_2 and K_2CO_3 10%. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated.

30 The residue (32g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/EtOAc$ 97/3; 20-45 μ m). The pure fractions were collected and the solvent was evaporated. The residue was taken up in petroleum ether. The precipitate was filtered off and dried, yielding 15g of residue (fraction 1). The mother layer was evaporated. The residue was combined with 14.1g of fraction 1, yielding 28.9 g of

35 1,6-dimethyl-2-(trifluoromethyl)-1*H*-imidazo[4,5-*b*]pyridine; mp. 100°C (interm. 19).

-50-

b) 1-Bromo-2,5-pyolidinedione (0.0735 mol) and dibenzoyl peroxide (1.5g) were added at room temperature to a solution of intermediate (19) (0.07 mol) in tetrachloromethane (450ml). The mixture was stirred and refluxed for 7 hours, then brought to room temperature and filtered. The reaction was carried out again using the same 5 quantities. The mixtures were combined. The solvent was evaporated. The residue (50g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 and 98/2; 20-45 μm). The pure fractions were collected and the solvent was evaporated, yielding 20.2g (49%) of 6-(bromomethyl)-1-methyl-2-(trifluoromethyl)-
1H-imidazo[4,5-*b*]pyridine (interm. 20).

10 c) A mixture of ethyl 4-(*1H*-benzimidazol-2-ylamino)-1-piperidine-carboxylate (0.0464 mol), intermediate (20) (0.051 mol) and potassium carbonate (0.1392 mol) in acetonitrile (250ml) was stirred and refluxed for 90 minutes and then brought to room temperature. Water was added and the mixture was extracted twice with CH_2Cl_2 . The combined organic layer was dried (MgSO_4), filtered and the solvent was evaporated.

15 The product was used without further purification, yielding 23g (>100%) of ethyl 4-[[1-[[1-methyl-2-(trifluoromethyl)-*1H*-imidazo[4,5-*b*]pyridin-6-yl]methyl]-*1H*-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 21).

Example A8

A mixture of ethyl 4-(*1H*-benzimidazol-2-ylamino)-1-piperidine-carboxylate (0.0289 mol), 7-chloro-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (0.0289 mol) and potassium carbonate (0.0867 mol) in acetonitrile (250ml) was stirred and refluxed for 48 hours and then brought to room temperature. The reaction was carried out again using the same quantities. The mixtures were combined, poured out into H_2O and extracted with EtOAc. The organic layer was separated, washed with H_2O , dried (MgSO_4), filtered 25 and the solvent was evaporated. The residue (25g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.5; 20-45 μm). Two fractions were collected and their solvents were evaporated, yielding 8g of ethyl 4-[[1-(6,7-dihydro-5*H*-1-pyridin-7-yl)-*1H*-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 22).

Example A9

a) A dispersion of sodium hydride in mineral oil (0.261 mol) was added portionwise at room temperature under N_2 flow to a mixture of *N*-8-quinolinylformamide (0.174 mol) in DMF (500ml). The mixture was stirred at room temperature for 1 hour. A solution of 1-chloro-2-nitrobenzene (0.53 mol) in DMF (200ml) was added dropwise. The 35 mixture was stirred at 140°C for 12 hours and then brought to room temperature. H_2O was added and the mixture was extracted with CH_2Cl_2 . The organic layer was

separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (110g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{cyclohexane}$ 80/20; 20-45 μm). The pure fractions were collected and the solvent was evaporated, yielding 9.8g (21%) of *N*-(2-nitrophenyl)-8-quinolinamine (interm. 23).

5 b) A mixture of 6-quinolinemethanamine (0.074 mol), 2-chloro-3-nitropyridine (0.0888 mol) and potassium carbonate (0.185 mol) in acetonitrile (200ml) was stirred and refluxed for 5 hours and then cooled to room temperature. EtOAc and H_2O were added. The mixture was extracted with HCl 3N. The aqueous layer was basified with K_2CO_3 solid and extracted with CH_2Cl_2 . The combined organic layer was dried (10 MgSO_4), filtered and the solvent was evaporated, yielding 17.8g (84%) of *N*-(3-nitro-2-pyridinyl)-8-quinolinemethanamine (interm. 24).

Example A10

a) A mixture of intermediate (24) (0.064 mol) in methanol (200ml) was hydrogenated under a 3 bar pressure for 2 hours with Raney nickel (10g) as a catalyst. After uptake (15) of hydrogen (3 equiv), the catalyst was filtered through celite and the filtrate was evaporated, yielding 14.8g (93%) of *N*2-(8-quinolinylmethyl)-2,3-pyridinediamine (interm. 25).

b) A mixture of intermediate (25) (0.059 mol) and ethyl 4-isothiocyanato-1-piperidine-carboxylate (0.059 mol) in methanol (150ml) was stirred and refluxed for 4 hours and (20) brought to room temperature. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 97/3; 20-45 μm). The desired fractions were collected and the solvent was evaporated, yielding 10.5g (37%) of ethyl 4-[[[[2-[(8-quinolinylmethyl)amino]-3-pyridinyl]amino]sulfinyl]-amino]-1-piperidine-carboxylate (interm. 26)

c) A mixture of intermediate (26) (0.026 mol), mercury(II) oxide (0.052 mol) and (25) sulfur (0.2g) in ethanol (120ml) was stirred and refluxed for 2 hours, brought to room temperature and filtered over celite. The filtrate was evaporated, yielding 8.7g (96%) of 4-[[1-(8-quinolinylmethyl)-1*H*-imidazo[4,5-*b*]pyridin-2-yl]amino]-1-piperidine-carboxylate (interm. 27).

30 Example A11

a) A mixture of 8-quinolinecarboxaldehyde (0.092 mol) and 4-methylbenzenesulfonic acid (0.3g) in 2-ethoxyethanol (110ml) was stirred and refluxed for 24 hours using a Dean Stark apparatus. The solvent was evaporated. The reaction was carried out again using the same quantities. The residues were combined and taken up in CH_2Cl_2 . The (35) organic solution was washed with K_2CO_3 10% and decanted. The organic layer was dried (MgSO_4), filtered and the solvent was evaporated. The residue (41g) was

-52-

purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98/2; 20-45 μm). Two pure fractions were collected and their solvents were evaporated, yielding 20g (34%) of 8-[bis(2-ethoxyethoxy)methyl]quinoline (interm. 28).

5 b) A mixture of 8-quinolinecarboxaldehyde (0.248 mol), triethoxymethane (0.4464 mol) and 4-methylbenzenesulfonic acid (4g) in ethanol (250ml) was stirred and refluxed for 1 hour, brought to room temperature, poured out into K_2CO_3 10% and extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The product was used without further purification, yielding 48.5g (80%) of 8-(diethoxymethyl)-quinoline (interm. 29).

10 c) A mixture of 2-quinolinecarboxaldehyde (0.08 mol) and 4-methylbenzenesulfonic acid (0.25g) in ethanol (100ml) was stirred and refluxed for 48 hours and brought to room temperature. The reaction was carried out again using the same quantities. The mixtures were combined. The solvent was evaporated. The residue was taken up in CH_2Cl_2 . The organic solution was washed with K_2CO_3 10% and with H_2O , then dried

15 (15) (MgSO_4), filtered and the solvent was evaporated. The product was used without further purification, yielding 32.5g of 2-(diethoxymethyl)quinoline (interm. 30).

Example A12

Intermediate (1) (0.0377 mol) and intermediate (29) (0.0755 mol) were heated at 160°C for 1 hour and then purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98/2; 15-35 μm). The pure fractions were collected and the solvent was evaporated, yielding 15g (79%) of (\pm)-1,1-dimethylethyl 4-[[1-[ethoxy(8-quinolinyl)methyl]-1*H*-benzimidazol-2-yl]amino]-1-piperidinecarboxylate (interm. 31).

Example A13

4-Methylbenzenesulfonyl chloride (0.2222 mol) was added portionwise at 10°C to a mixture of 1,1-dimethylethyl [1-(hydroxymethyl)-2-methylpropyl]carbamic acid (ester) (0.202 mol) in pyridine (65ml). The mixture was stirred at 10°C for 2 hours. H_2O (75ml) was added at 10°C. The precipitate was filtered off, washed with H_2O and taken up in CH_2Cl_2 . The organic solution was washed with H_2O , dried, filtered and the solvent was evaporated, yielding 49g (68%) of (\pm)-1,1-dimethylethyl [1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-2-methylpropyl]carbamate; mp. 85°C (interm. 32).

Example A14


a) A mixture of compound (33) (0.0347 mol), 1-bromo-3-methyl-2-butanone (0.052 mol) and potassium carbonate (0.104 mol) in acetonitrile (255ml) was stirred and refluxed for 2 hours and filtered. The filtrate was evaporated. The residue was taken up in H_2O and the mixture was extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The product was

used without further purification, yielding 16.84g of (\pm)-1-[4-[[1-[ethoxy(8-quinoliny) methyl]-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone (interm. 34) (quant.).


In a similar way were also prepared :

- 5 1-[4-(1*H*-benzimidazol-2-ylamino)-1-piperidinyl]-3-methyl-2-butanone; 1-[4-[[1-(8-quinoliny)-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone; and 1-[4-[[1-(2-quinoliny)methyl]-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone.
- 10 10 b) A mixture of intermediate (34) (0.036 mol) in methanol (200ml) was stirred at 10°C. Sodium tetrahydroborate (0.04 mol) was added portionwise. The mixture was stirred for 90 minutes. H₂O was added. The solvent was evaporated. The residue was extracted with CH₂Cl₂. The organic layer was separated, washed with H₂O, dried (MgSO₄), filtered and the solvent was evaporated, yielding 17g (96%) of (\pm)-4-[[1-ethoxy(8-quinoliny)methyl]-1*H*-benzimidazol-2-yl]amino]-alpha-(1-methylethyl)-1-piperidineethanol (interm. 35).
- 15 c) Diethyl azodicarboxylate (0.015 mol) was added dropwise at 0°C under N₂ flow to a solution of intermediate (35) (0.01 mol), phthalimide (0.015 mol) and triphenylphosphine (0.015 mol) in tetrahydrofuran (100ml). The mixture was stirred at room
- 20 temperature for 2 hours. EtOAc was added. The mixture was extracted with HCl 3N and separated into its layers. The aqueous layer was washed twice with EtOAc, basified with K₂CO₃ solid and extracted with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.2; 20-45 μ m). Two pure fractions were collected and their solvents were evaporated, yielding 2.3g (30%) of (\pm)-2-[2-[4-[[1-[ethoxy(8-quinoliny)methyl]-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methylbutyl]-1*H*-isoindole-1,3(2*H*)dione (interm.
- 25

d) Preparation of intermediate




A solution of



(0.024 mol) (prepared according to A14b)

and Et_3N (0.072 mol) in CH_2Cl_2 (100ml) was cooled to 0°C under N_2 flow. A mixture of methanesulfonyl chloride (0.036 mol) in CH_2Cl_2 (a small amount) was added dropwise. The mixture was allowed to cool to room temperature while stirring for 3 hours. Water was added. The mixture was decanted. The organic layer was dried 5 (MgSO_4), filtered and the solvent was evaporated, yielding 8.5g of intermediate (80) (86%).

e) Preparation of intermediate



A solution of 1*H*-isoindole-1,3(2*H*)-dione (0.0828 mol) in DMF (80ml) was cooled to 10°C. NaH 60% in oil (0.0828 mol) was added portionwise. The mixture was allowed 10 to cool to room temperature while stirring for 1 hour. A mixture of intermediate (80) (0.0207 mol) (prepared according to A14d) in DMF (a small amount) was added dropwise. The mixture was stirred at room temperature for 1.5 hours, at 60°C for 5 hours and at room temperature for the weekend. The residue (9.6g) was crystallized from diethyl ether and CH_3CN . The precipitate was filtered off and dried, yielding 4g of 15 intermediate (81) (42%).

Example A15

a) A mixture of 1-[4-(1*H*-benzimidazol-2-ylamino)-1-piperidinyl]-3-methyl-2-butanone (0.03 mol) and benzenemethanamine (0.09 mol) in methanol (200ml) was hydrogenated at 40°C under a 3 bar pressure for 48 hours with palladium on activated 20 carbon (1.3g) as a catalyst. After uptake of hydrogen, the catalyst was filtered through celite, washed with CH_3OH and the filtrate was evaporated. Hydrogenation was continued for 24 hours. After uptake of hydrogen, the catalyst was filtered through celite, washed with CH_3OH and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 85/14/1; 25 20-45 μm). The desired fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.4g of (\pm)-*N*-(1-(2-amino-3-methylbutyl)-4-piperidinyl)-1*H*-benzimidazol-2-amine; mp. 138°C (interm. 37).

b) Di-tert-butyl dicarbonate (0.02 mol) was added at 5°C to a mixture of intermediate 30 (37) (0.0186 mol) in dichloromethane (60ml). The mixture was stirred at room temperature for 3 hours and poured out into H_2O . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The product was used without

further purification, yielding 5.9g of (\pm)-1,1-dimethylethyl [1-[[4-[[1-[(1,1-dimethyl-ethoxy)carbonyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]methyl]-2-methyl-propyl]carbamate (interm. 38).

Example A16

5 A mixture of 1-[4-[[1-(8-quinoliny)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone (0.0222 mol) and benzenemethanamine (0.0666 mol) in methanol (250ml) was hydrogenated at 40°C under a 3 bar pressure for 24 hours with palladium on activated carbon (1.5g) as a catalyst. After uptake of hydrogen, the catalyst was filtered through celite, washed with CH₂Cl₂ and CH₃OH and the filtrate was

10 evaporated. Palladium on activated carbon (1.5g) and methanol (250ml) were added again. Hydrogenation was continued at 40°C under a 3 bar pressure for 24 hours. After uptake of hydrogen, the catalyst was filtered through celite, washed with CH₂Cl₂ and the filtrate was evaporated. The residue (22g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 95/5/0.1 and

15 85/15/1; 20-45 μ m). Three pure fractions were collected and their solvents were evaporated, yielding 2.6g 1-[4-[[1-(1,2,3,4-tetrahydro-8-quinoliny)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone (interm. 40) (fraction 1), 2.9g of fraction 2 and 0.7g of fraction 3. Fraction 2 and 3 were crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 0.82g (\pm)-N-[1-[3-methyl-2-

20 [(phenylmethyl)amino]butyl]-4-piperidinyl]-1-(1,2,3,4-tetrahydro-8-quinoliny)-1H-benzimidazol-2-amine ; mp. 126°C and 0.55g of N-(4-piperidinyl)-1-(1,2,3,4-tetrahydro-8-quinoliny)-1H-benzimidazol-2-amine; mp. 205°C (comp. 48).

Example A17

a) A mixture of *N*-(4-piperidinyl)-1-(4-quinolinylmethyl)-1H-benzimidazol-2-amine (comp. 23) (0.0129 mol), chloroacetonitrile (0.0155 mol), potassium iodide (0.00129 mol) and potassium carbonate (0.0258 mol) in 4-methyl-2-pentanone (80ml) was stirred and refluxed for 5 hours. H₂O was added. The solvent was evaporated. H₂O and CH₂Cl₂ were added. The precipitate was filtered off. The filtrate was separated into its layers. The organic layer was dried (MgSO₄), filtered and the solvent was


25 evaporated. The residue (3.5g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/ CH₃OH/NH₄OH 95/5/0.3; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried, yielding 0.94g 4-[[1-(4-quinolinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidineacetonitrile; mp. 190°C (interm. 41).

30 b) A mixture of *N*-(4-piperidinyl)-[1,2'-bi-1H-benzimidazol]-2-amine (comp. 71) (0.01 mol), chloroacetonitrile (0.01 mol) and sodium hydrogen carbonate (0.02 mol) in

DMF (50ml) was stirred at 50°C overnight. The solvent was evaporated. The residue was taken up in H₂O and the mixture was extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was suspended in DIPE, filtered off and dried, yielding 2.3g (63%) of product. This 5 fraction was purified over silica gel on a glass filter (eluent: CH₂Cl₂/(CH₃OH/NH₃) 97/3). The pure fractions were collected and the solvent was evaporated, yielding 1.36g (37%) of 4-[(1,2'-bi-1H-benzimidazol-2-yl)amino]-1-piperidine-acetonitrile (interm. 42).

Example A18


Preparation of intermediate



10 A mixture of 2-chloro-1H-benzimidazole (0.0189 mol) and 1,1-dimethylethyl 2-aminocyclohexanecarbamoate (0.04725 mol) (prepared according to A1a)) was stirred at 140°C for 3 hours, then brought to room temperature and taken up in CH₂Cl₂/CH₃OH. The same procedure was repeated 3 times on the same quantities of 2-chloro-1H-benzimidazole and 1,1-dimethylethyl 2-aminocyclohexanecarbamoate. 15 The mother layers were brought together, dried (MgSO₄), filtered and the solvent was evaporated. The residue (28g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 96/4/0.1; 15-35μm). Two fractions were collected and the solvent was evaporated, yielding 4.5g of intermediate (84) (24%).

Example A19


Preparation of intermediate




20 A mixture of quantities of ethyl 4-(1H-benzimidazol-2-ylamino)-1-piperidine-carboxylate (0.0154 mol), (0.0154 mol) (prepared according to A14d) and K₂CO₃ (0.0463 mol) in CH₃CN (50ml) and DMF (5ml) was stirred and refluxed for 6 hours, poured out into H₂O and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3; 35-70μm). The pure fractions were collected and the solvent was evaporated, yielding: 0.87g of intermediate (76) (13%). 25

Example A20

a) Preparation of intermediate




A solution of



(0.0105 mol) (prepared according to

A1b) in HCl 6N (60ml) was stirred and refluxed for 12 hours and then brought to room temperature. The solvent was evaporated. The residue was taken up in 2-propanol. The precipitate was filtered off, washed with CH_3CN , washed with diethyl ether and dried, 5 yielding: 4g of intermediate (82) (94%).


b) Preparation of intermediate



Intermediate (82) (0.0094 mol) was added at room temperature to CH_2Cl_2 (70ml). Et_3N (0.0188 mol) was added. 1,1'-carbonylbis-1*H*-imidazole (0.0188 mol) was added. The mixture was stirred at room temperature for 4.5 hours. (Methylamino)acetonitrile .HCl (0.0188 mol) was added. The mixture was stirred at room temperature for 12 hours. The 10 organic layer was separated, washed twice with water, dried (MgSO_4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98.5/1.5; 35-70 μm). The pure fractions were collected and the solvent was evaporated. The residue (2.2g) was crystallized from CH_3CN . The precipitate was filtered off and dried, yielding: 1.5g of intermediate (83) 15 (41%).

Example A21


A mixture of intermediate



(interm. 85) (0.0461 mol)

(prepared according to A1b) in HCl 3 N (200ml) was stirred and refluxed for 1 hour. The solvent was evaporated. The residue was taken up in EtOAc and NH4OH. The mixture was stirred for 30 minutes and filtered. The solvent was evaporated. The product was used


without further purification, yielding 14g of



5

Tables 1, 2 and 3 list intermediates which were prepared analogous to one of the above examples.

Table 1









Int. No.	Ex. No.	R ^a	R ^b	R ^c	n	a	*	b	R ^d	R ^e	R ^f	R ^g
43	A10c	H	H	H	1	N	2	C	-	H	H	H
44	A12	CH ₃	H	O(CH ₂) ₂ OC ₂ H ₅	1	CH	8	C	H	H	H	-
45	A12	CH ₃	H	O(CH ₂) ₂ OC ₂ H ₅	1	CH	2	C	-	H	H	H
46	A7c	CH ₃	H	H	1	CH	2	N	-	OCH ₃	-	H
47	A7c	H	H	H	1	CH	2	C	-	H	H	Cl
48	A7c	H	H	H	1	CH	2	C	-	H	Cl	H
49	A7c	H	H	H	1	CH	2	C	-	H	H	H
2	A1b	CH ₃	H	H	1	CH	2	C	-	H	H	H
50	A12	CH ₃	CH ₃	OC ₂ H ₅	1	CH	8	C	H	H	H	-
51	A12	CH ₃	H	OC ₂ H ₅	1	CH	2	C	-	H	H	H
52	A12	CH ₃	H	OC ₂ H ₅	1	CH	2	C	-	OCH ₃	H	H
31	A12	CH ₃	H	OC ₂ H ₅	1	CH	8	C	H	H	H	-
53	A3f	H	H	H	1	CH	8	C	H	H	H	-
54	A3f	CH ₃	H	H	1	CH	8	N	H	H	-	

Int. No.	Ex. No.	R ^a	R ^b	R ^c	n	a	*	b	R ^d	R ^e	R ^f	R ^g
55	A7c	CH ₃	H	H	1	CH	8	C	CH ₃	H	H	-
11	A3f	CH ₃	H	H	1	CH	8	N	CH ₃	CH ₃	-	-
56	A7c	H	H	H	1	CH	4	C	H	H	-	H
57	A7c	H	CH ₃	H	1	CH	8	C	H	H	H	-
27	A10c	H	H	H	1	N	8	C	H	H	H	-
58	A10c	H	H	-	0	CH	8	C	H	H	H	-
66	A12	CH ₃	CH ₃	O(C ₂ H ₅)OC ₂ H ₅	1	CH	8	C	H	H	H	-
67	A12	CH ₃	H	O(C ₂ H ₅)OC ₂ H ₅	1	CH	8	C	H	H	H	-
68	A1b	CH ₃	CH ₃	CH ₃	1	CH	8	C	H	H	H	-
69	A1b	CH ₃	H	H	1	CH	2	C	-	OCH ₃	H	H
70	A1b	CH ₃	H	H	1	CH	2	N	-	H	-	H
71	A1b	CH ₃	H	H	1	CH	8	C	OCH ₃	H	H	-

* = position bicyclic heterocycle

Table 2



Int. No.	Ex. No.	R ^a	R ^b	n	L
59	A2c	CH ₃	H	0	
60	A8	H	H	0	
61	A2c	H	H	0	
5	A2c	CH ₃	H	0	
21	A7c	H	H	1	

-60-





Int. No.	Ex. No.	R ^a	R ^b	n	L
62	A3f	CH ₃	H	1	
63	A7c	CH ₃	H	1	
64	A7c	H	H	1	
65	A2c	CH ₃	H	0	
22	A8	H	H	0	
72	A2c	CH ₃	CH ₃	0	
73	A2c	CH ₃	CH ₃	0	
74	A2c	CH ₃	CH ₃	0	
75	A2c	CH ₃	CH ₃	0	
76	A19	H	H	1	

Table 3



Int. No.	Ex. No.	L	Physical data
77	A1b		
78	A1b		
79	A1b		trans
80	A14d		
81	A14e		
82	A20		
83	A20		

B. Preparation of the final compounds

Example B1

a) A mixture of 2-propanol and hydrochloric acid (15ml) was added to a mixture of 5 intermediate (2) (0.0284 mol) in 2-propanol (150ml). The mixture was stirred and refluxed for 90 minutes and cooled. The precipitate was filtered off, washed with 2-propanol and DIPE and dried, yielding 10.36g of *N*-(4-piperidinyl)-1-(2-quinolinylmethyl)-1*H*-benzimidazol-2-amine dihydrochloride (comp.1).

b) A mixture of compound (1) (0.01 mol) and sodium carbonate (0.03 mol) in 10 4-methyl-2-pentanone (250ml) was stirred and refluxed for a few hours using a water separator (until gas development stops). 2-Bromoethyl carbamic acid 1,1-dimethyl-ethyl ester (0.015 mol) was added. The mixture was stirred and refluxed for 18 hours using a water separator, then cooled, washed with H₂O, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/C₂H₅OH 95/5 and 90/10). The pure fractions were collected and the solvent was evaporated, yielding 3.8g of 1,1-dimethylethyl [2-[4-[[1-(2-quinolinylmethyl)-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]carbamate (comp. 2).

c) A mixture of compound (2) (0.0076 mol) in a mixture of 2-propanol and hydrochloric acid (10ml) and 2-propanol (100ml) was stirred and refluxed for 1 hour

and then cooled. The precipitate was filtered off, washed with 2-propanol and DIPE and dried, yielding 3.08g of *N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(2-quinolinylmethyl)-1*H*-benzimidazol-2-amine tetrahydrochloride monohydrate (comp. 3).

d) A mixture of compound (115) (0.00305 mol) in HBr/HOAc 33% (34ml) was stirred 5 at room temperature for 2 hours, poured out on ice, basified with a concentrated NH₄OH solution and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2; 15-40 µm). Two fractions (F1 and F2) were collected and their solvents were evaporated, yielding 10 0.56g F1 (46%) and 0.69g F2 (50%). F1 was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.27g of (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-amine (comp. 116).

e) A mixture of compound (155) (0.0024 mol) in CH₃OH (3ml) and 2-propanol (15ml) 15 was stirred and refluxed for 2 hours, filtered, washed with 2-propanol and dried. The residue (1.05g) was taken up in CH₂Cl₂ and basified with NH₄OH. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.42g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 85/15/2; 15-40 µm). The pure fractions were collected and the solvent 20 was evaporated. The residue (0.35g) was dissolved in CH₃OH and converted into the ethanedioic acid salt. The precipitate was filtered off and dried. This fraction was taken up in water and CH₂Cl₂ and alkalized with K₂CO₃ 10%. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.21g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ 25 NH₄OH 75/28/1; 15-40 µm). The pure fractions were collected and the solvent was evaporated, yielding 0.13g of compound (156).

Example B2

A mixture of intermediate (27) (0.02 mol) in hydrochloric acid (6N) (85ml) was stirred and refluxed at 50°C overnight and then brought to room temperature. The solvent 30 was evaporated. The residue was taken up in K₂CO₃ 10% and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated, yielding 5g (69%) of *N*-(4-piperidinyl)-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine (comp. 41).

Example B3

35 A mixture of intermediate (41) (0.00668 mol) in a solution of ammonia in methanol (7N) (70ml) was hydrogenated at room temperature under a 3 bar pressure for 5 hours

with Raney nickel (2.7g) as a catalyst. After uptake of hydrogen (2 equiv.), the catalyst was filtered through celite, washed with CH₂Cl₂ and CH₃OH and the filtrate was evaporated. The residue was taken up in CH₂Cl₂ and a small amount of CH₃OH. The organic solution was washed with H₂O, dried (MgSO₄), filtered and the solvent was 5 evaporated. The residue was crystallized from EtOAc. The precipitate was filtered off and dried, yielding 1.6g (60%) of *N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-quinolinyl-methyl)-1*H*-benzimidazol-2-amine ; mp. 196°C (comp. 24).

Example B4

A mixture of intermediate (36) (0.00351 mol) in hydrazine (2.5ml) and ethanol (30ml) 10 was stirred and refluxed for 20 minutes and brought to room temperature. Ice water was added. The mixture was extracted with CH₂Cl₂ and separated into its layers. The aqueous layer was washed twice with CH₂Cl₂. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was taken up in diethyl 15 ether. The precipitate was filtered off and dried, yielding 1g of (±)-*N*-[1-[1-(amino-methyl)-2-methylpropyl]-4-piperidinyl]-1-[ethoxy(8-quinolinyl)methyl]-1*H*-benzimidazol-2-amine; mp. 202°C (comp. 100).

Example B5

Intermediate (32) (0.1382 mol) was added at 55°C to a mixture of (±)-1-[ethoxy(3-methoxy-2-quinolinyl)methyl]-*N*-(4-piperidinyl)-1*H*-benzimidazol-2-amine (0.0346 20 mol) and potassium carbonate (0.242 mol) in acetonitrile (108ml) and DMF (20ml) (1 equiv of intermediate (32) was added every hour). The mixture was stirred at 55°C for 1 hour and filtered. The filtrate was poured out into H₂O and the mixture was extracted with EtOAc. The organic layer was separated, washed with a saturated NaCl solution, dried (MgSO₄), filtered and the solvent was evaporated. The residue was 25 purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 98/2/0.4 and 96/4/0.5; 20-45 µm). Two fractions were collected and their solvents were evaporated, yielding 2.5g (23%) of (±)-1,1-dimethylethyl [1-[[4-[[1-[ethoxy(3-methoxy-2-quinolinyl)methyl]-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]methyl]-2-methylpropyl]carbamate (comp. 38).

30 Example B6

A mixture of 1-[4-[[1-(2-quinolinylmethyl)-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone (0.0158 mol) and benzenemethanamine (0.0474 mol) in methanol (150ml) was hydrogenated at 40°C under a 3 bar pressure for 48 hours with palladium on activated carbon (0.7g) as a catalyst. After uptake of hydrogen (1 35 equiv), the catalyst was filtered through celite, washed with CH₂Cl₂/ CH₃OH and the filtrate was evaporated. The residue (11.5g) was purified by column chromatography

over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 94/6/0.5; 20–45 μm). The pure fractions were collected and the solvent was evaporated, yielding 4g of residue. This fraction was converted into the hydrochloric acid salt with 2-propanol/ HCl. The precipitate was filtered off and dried, yielding 5.1g of product. This fraction was

5 converted into the free base and then purified by column chromatography over C_{18} (eluent: $\text{CH}_3\text{OH}/\text{NH}_4\text{OAc}$ 60/40 and 80/20; column: KROMASIL C18). Two pure fractions were collected and their solvents were evaporated, yielding 0.8g of fraction 1 and 2g of fraction 2. Fraction 1 was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.5g of (\pm)- N -[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-quinolinylmethyl)-1*H*-benzimidazol-2-amine; mp. 135°C (comp. 6).

10 Fraction 2 was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:4). The precipitate was filtered off and dried, yielding 2.2g of (\pm)- N -[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(1,2,3,4-tetrahydro-2-quinolinyl)methyl]-1*H*-benzimidazol-2-amine tetrahydrochloride monohydrate; mp. 230°C (comp. 46).

15 **Example B7**

a) A dispersion of sodium hydride in a mineral oil (60%) (0.01 mol) was added portionwise at 0°C under N_2 flow to a mixture of intermediate (38) (0.005 mol) in DMF (25ml). The mixture was stirred at room temperature for 1 hour. A solution of 2-(bromomethyl)-3-methoxyquinoline (0.0055 mol) in DMF (10ml) was added

20 dropwise. The mixture was stirred at room temperature for 2 hours, hydrolyzed with K_2CO_3 10% and extracted with EtOAc. The organic layer was separated, washed with NaCl, dried (MgSO_4), filtered and the solvent was evaporated, yielding 4.5g (>100%) of (\pm)-1,1-dimethylethyl [1-[[4-[[1-[(3-methoxy-2-quinolinyl)methyl]-1*H*-benzimidazol-2-yl]-amino]-1-piperidinyl]methyl]-2-methylpropyl]carbamate (comp. 14).

25 b) A dispersion of sodium hydride in a mineral oil (60%) (0.014 mol) was added portionwise at 0°C under N_2 flow to a mixture of intermediate (38) (0.007 mol) in DMF (30ml). The mixture was stirred at 5°C for 1 hour. A solution of (\pm)-2,8-di-bromo-5,6,7,8-tetrahydroquinoline (0.0084 mol) in DMF (10ml) was added dropwise. The mixture was stirred at room temperature for 2 hours. H_2O and EtOAc were added.

30 The organic layer was separated, washed with a saturated NaCl solution, dried (MgSO_4), filtered and the solvent was evaporated. The residue (5.6g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.5; 20–45 μm). The pure fractions were collected and the solvent was evaporated, yielding 1.1g (25%) of (\pm)-1,1-dimethylethyl [1-[[4-[[1-(2-bromo-5,6,7,8-tetrahydro-8-quinolinyl)-1*H*-benzimidazol-2-yl]amino]-1-piperidinyl]methyl]-2-methylpropyl]carbamate (comp. 55).

35

c) A mixture of intermediate 84 (0.0145 mol), 8-bromomethylquinoline (0.0174 mol) and K_2CO_3 (0.029 mol) in CH_3N (70ml) was stirred and refluxed for 4 hours, then brought to room temperature. The solvent was evaporated. The residue was taken up in H_2O and extracted twice with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), 5 filtered and the solvent was evaporated. The residue was crystallized from diethyl ether/ CH_3CN . The precipitate was filtered off and dried, yielding 5.07g of compound 79 (74%).

Example B8

c) (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(5,6,7,8-tetrahydro-3-methoxy-10 2-quinolinyl)methyl]-1*H*-benzimidazol-2-amine tetrahydrochloride monohydrate (0.00218 mol) was basified with K_2CO_3 10%. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated, to give A'. A mixture of A' in dichloromethane (50ml) was cooled to 0°C. A solution of tribromoborane in dichloromethane (0.01526 mol) was added dropwise. 15 The mixture was stirred at room temperature overnight, poured out on ice, basified with a concentrated NH_4OH solution, decanted and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (1.1g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 90/10/0.5; 20-45 μ m). The desired fractions were collected 20 and the solvent was evaporated. The residue was converted into the hydrochloric acid salt (1:4) with $HCl/2$ -propanol. The precipitate was filtered off and dried, yielding 0.5g (37%) of (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(5,6,7,8-tetrahydro-3-hydroxy-2-quinolinyl)methyl]-1*H*-benzimidazol-2-amine tetrahydro-chloride monohydrate; mp. 240°C (comp. 63).

25 Example B9

a) A mixture of compound 158 (0.0089 mol) in HCl 3N (40ml) was stirred at 100°C for 12 hours, then brought to room temperature and poured out on ice and NH_4OH . $EtOAc$ was added. The precipitate was filtered off, washed with $EtOAc$ and dried, yielding 2g of compound 159.


30 b) A mixture of compound 168 (0.00895 mol) in HCl 3N (35ml) was stirred at 100°C for 24 hours. The solvent was evaporated. The residue was taken up in $EtOAc$. The mixture was basified with NH_4OH . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. Part of this fraction (0.7g) was crystallized from CH_3CN . The precipitate was filtered off and dried, yielding 0.3g of compound 35 167.

-66-

c) A mixture of compound 176 (0.00373 mol) in HCl 3N (20ml) was stirred at 100°C for 12 hours, brought to room temperature, poured out on ice, basified with NH₄OH and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. This fraction was dissolved in 2-propanol and 5 converted into the hydrochloric acid salt (1:3). The precipitate was filtered off and dried, yielding 1.5g of compound 173 (77%).

Example B10

A mixture of intermediate




(interm. 87) (0.002 mol)

(prepared according to A1b)), 1,2-ethanediamine (0.02 mol) and NaCN (0.0002 mol) in CH₃OH (7ml) was heated at 45°C for 4 hours and then brought to room temperature.

10 Water was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.65g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 90/10/1; 35-70 µm). The pure fractions were collected and the solvent was evaporated, yielding 0.42g of compound 170 (56%)

15 Example B11

A mixture of intermediate



(interm. 88) (0.0077 mol)

(prepared according to A14a)) and formic acid/NH₃ (0.0462 mol) in formamide (35ml) was stirred at 140°C for 30 min and then brought to room temperature. CH₂Cl₂ was added. The organic layer was separated, washed with K₂CO₃ 10%, dried (MgSO₄), filtered and the solvent was evaporated. The residue (4g) was purified by column


20 chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1; 15-40 µm). Two pure fractions were collected and their solvents were evaporated. The second fraction was crystallized from CH₃CN and diethyl ether. The precipitate was filtered off and dried, yielding: 1.37g of compound 137 (46%).

Example B12

Isopropyl titanate (IV) (0.0294 mol) was added at room temperature to a mixture of intermediate 85 (0.0245 mol) and 1-acetyl piperazine (0.027 mol) in CH_2Cl_2 (50ml) and ethanol (50ml). The mixture was stirred at room temperature for 7 hours. NaBH_3CN (0.0245 mol) was added portionwise. The mixture was stirred at room temperature for 5 12 hours. H_2O was added. The mixture was filtered over celite and washed with CH_2Cl_2 . The filtrate was separated into its layers. The organic layer was dried (MgSO_4), filtered and the solvent was evaporated. The residue (6.7g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.2; 15-40 μm). The pure fractions were collected and the solvent was evaporated. This fraction was 10 crystallized from 2-propanone. The precipitate was filtered off and dried, yielding: 0.64g of compound 176.

Tables 4 to 13 list the compounds of formula (I) which were prepared according to one of the above examples.

15 Table 4




Comp No.	Ex. No.	a	R ^a	R ^b	*	R ^c	Physical data
1	Bla	CH	H	H	2	H	HC1 (1:2)
2	Blb	CH	H	H	2	**	
3	Blc	CH	H	H	2	$\text{CH}_2\text{CH}_2\text{NH}_2$	$\text{HCl}(1:4);\text{H}_2\text{O}(1:1)$
4	Bla	CH	H	H	8	H	
5	Bla	CH	H	H	2	H	
6	B5	CH	H	H	2	$\text{CH}_2\text{CH}(2\text{-propyl})\text{NH}_2$	
7	B3	CH	H	H	8	$\text{CH}(2\text{-propyl})\text{CH}_2\text{NH}_2$	
8	B3	CH	H	H	2	$\text{CH}(2\text{-propyl})\text{CH}_2\text{NH}_2$	H_2O (1:1)
9	Bla	CH	H	8-Cl	2	H	HCl (1:2)
10	Blc	CH	H	H	8	$\text{CH}_2\text{CH}(2\text{-propyl})\text{NH}_2$	
11	B3	CH	H	8-Cl	2	$\text{CH}(2\text{-propyl})\text{CH}_2\text{NH}_2$	
12	Bla	CH	4-OH	H	2	H	



Comp No.	Ex. No.	a	R ^a	R ^b	*	R ^c	Physical data
13	B3	CH	H	8-C1	2	CH ₂ CH(2-propyl)NH ₂	
14	B6a	CH	3-OCH ₃	H	2	(C=O)OC(CH ₃) ₃	
15	Blc	CH	3-OCH ₃	H	2	CH ₂ CH(2-propyl)NH ₂	
16	B6a	N	3-CH ₃	H	2	***	
17	Bla	CH	H	H	8	H	HC1 (1:3)
18	Bla	N	H	H	8	H	
19	Blc	N	H	H	8	CH ₂ CH(2-propyl)NH ₂	HCl(1:3); H ₂ O(1:3)
20	Bla	N	3-OCH ₃	H	2	H	
21	B4	N	3-OCH ₃	H	2	***	
22	Blc	N	3-OCH ₃	H	2	CH ₂ CH(2-propyl)NH ₂	
23	Bla	CH	H	H	4	H	
24	B2	CH	H	H	4	CH ₂ CH ₂ NH ₂	
88	Bla	N	2-CH ₃	3-CH ₃	8	H	
89	Blc	N	2-CH ₃	3-CH ₃	8	CH ₂ CH(2-propyl)NH ₂	HCl(1:4); H ₂ O(1:2)
90	Bla	CH	2-CH ₃	H	8	H	
91	B1c	CH	2-CH ₃	H	8	CH ₂ CH(2-propyl)NH ₂	H ₂ O (1:1)
92	B2	CH	2-CH ₃	H	8	CH ₂ CH ₂ NH ₂	
104	B3	CH	H	H	8	CH ₂ CH(2-propyl)NH ₂	
105	B3	CH	H	H	8	CH(2-propyl)CH ₂ NH ₂	
106	B1c	N	3-CH ₃	H	2	CH ₂ CH(2-propyl)NH ₂	H ₂ O (1:2)
109	B5	CH	H	H	8	***	
110	B5	N	2-CH ₃	3-CH ₃	8	***	
111	B5	CH	2-CH ₃	H	8	***	
112	B5	N	H	H	8	***	
113	B7	CH	H	H	8	***	

- * position bicyclic heterocycle
- ** (CH₂)₂NH(C=O)OC(CH₃)₃
- *** CH₂CH(2-propyl)NH(C=O)OC(CH₃)₃

Table 5




Comp No.	Ex. No.	a	R ^a	R ^b	*	R ^c	G	Physical data
25	B1a	CH	H	H	2	H	CHOC ₂ H ₅	
26	B3	CH	H	H	2	CH(2-propyl)CH ₂ NH ₂	CHOC ₂ H ₅	H ₂ O (1:1)
27	B3	CH	H	H	2	CH ₂ CH(2-propyl)NH ₂	CHOC ₂ H ₅	
28	B1a	CH	H	H	2	H	***	
29	B3	CH	H	H	2	CH(2-propyl)CH ₂ NH ₂	***	H ₂ O (1:1)
30	B1a	CH	H	H	8	H	***	
31	B3	CH	H	H	8	CH ₂ CH(2-propyl)NH ₂	***	
32	B3	CH	H	H	8	CH(2-propyl)CH ₂ NH ₂	***	
33	B1a	CH	H	H	8	H	CHOC ₂ H ₅	
34	B1a	CH	3-OCH ₃	H	2	H	CHOC ₂ H ₅	
35	B1a	N	H	H	2	H	CH ₂	
36	B4	N	H	H	2	**	CH ₂	
37	B1c	N	H	H	2	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl (1:4)
38	B4	CH	3-OCH ₃	H	2	**	CHOC ₂ H ₅	
39 ⁽⁹⁾	B1c	CH	3-OCH ₃	H	2	CH ₂ CH(2-propyl)NH ₂	CHOC ₂ H ₅	HCl (1:3); H ₂ O (1:2)
40	B2	N	H	H	2	CH ₂ CH ₂ NH ₂	CH ₂	
41	B1a	N	H	H	8	H	CH ₂	
42	B1c	N	H	H	8	CH ₂ CH(2-propyl)NH ₂	CH ₂	
43	B1a	CH	H	CH ₃	8	H	CH ₂	
44	B1a	CH	H	CH ₃	8	H	CHOC ₂ H ₅	
45	B2	N	H	H	8	CH ₂ CH ₂ NH ₂	CH ₂	
100	B3	CH	H	H	8	CH(2-propyl)CH ₂ NH ₂	CHOC ₂ H ₅	
107	B1c	CH	H	H	8	CH ₂ CH(2-propyl)NH ₂	CHOC ₂ H ₅	
115	B5	CH	H	CH ₃	8		CH ₂	
116	B1d	CH	H	CH ₃	8	CH ₂ CH(2-propyl)NH ₂	CH ₂	

Comp No.	Ex. No.	a	R ^a	R ^b	*	R ^c	G	Physical data
117	B1d	CH	H	CH ₃	8	CH=O	CH ₂	
118	B1d	CH	H	CH ₃	8	CH ₂ CH ₂ NH ₂	***	H ₂ O(1:1)
119	B1d	CH	H	CH ₃	8	CH ₂ CH(2-propyl)NH ₂	***	
120	B3	N	H	CH ₃	8	CH ₂ CH ₂ NH ₂	CH ₂	HCl(1:4); H ₂ O(1:3)
121	B1d	CH	H	CH ₃	8	CH=O	***	
122	B1c	N	H	CH ₃	8	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:4); H ₂ O(1:1)
123	B1d	CH	H	CH ₃	8	CH ₂ CH ₂ NH ₂	CH ₂	
124	B1c	CH	H	H	8	CH ₂ CH ₂ NH ₂	***	HCl(1:3); H ₂ O(1:2)
125	B1c	CH	H	CH ₃	8	CH ₂ CH ₂ NH ₂	CHCH ₃	H ₂ O(1:1)
126	B1d	CH	3-OCH ₃	H	2	CH ₂ CH ₂ NH ₂	CH ₂	H ₂ O(1:2)
127	B1c	CH	4-CH ₃	H	2	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:4); H ₂ O(1:1)
128	B1c	CH	H	H	8	CH ₂ CH ₂ NH ₂	CH ₂	HCl(1:4); H ₂ O(1:1)
129	B1c	CH	H	H	8	CH ₂ CH ₂ NH ₂	CHCH ₃	H ₂ O(1:1)
130	B1c	CH	4-CH ₃	H	2	CH ₂ CH ₂ NH ₂	CH ₂	HCl(1:4); H ₂ O(1:2)
131	B1c	CH	H	H	4	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:4); H ₂ O(1:2)
131	B1b	CH	H	CH ₃	8		CH ₂	
132	B1b	CH	H	H	8		CH ₂	
133	B2	CH	H	H	8	H	CHCH ₃	HCl(1:2); H ₂ O(1:2)
134	B1c	CH	H	H	2	CH ₂ CH ₂ NH ₂	CHCH ₃	H ₂ O(1:1)
135	B2	CH	4-CH ₃	H	2	H	CH ₂	HCl(1:2)
136	B2	N	H	CH ₃	8	H	CH ₂	
137	B11	CH	H	H	8	CH=O	CH ₂	

* position quinoline

** CH₂CH(2-propyl)NH(C=O)OC(CH₃)₃*** CHO(CH₂)₂OC₂H₅


Table 6



Comp. No.	Ex. No.	*	G	R ^a	Physical data
46	B5	2	CH ₂	CH ₂ CH(2-propyl)NH ₂	HCl(1:4);H ₂ O(1:1)
47	B5	8	CH ₂	CH ₂ CH(2-propyl)NH ₂	HCl(1:4);H ₂ O(1:1)
48	B5	8	-	H	
49	B5	8	-	CH ₂ CH(2-propyl)NH ₂	H ₂ O (1:1)

* position bicyclic heterocycle

5 Table 7




Co. No.	Ex. No.	*	a	R ^a	G	R ^b	R ^c	Physical data
50	B1a	8	CH	H	-	H	H	
51	B5	8	CH	H	-	CH ₂ CH(2-propyl)NH ₂	H	
52	B1a	8	N	H	-	H	H	HCl (1:3)
53	B3	8	N	H	-	CH(2-propyl)CH ₂ NH ₂	H	
54 ⁽³⁾	B3	8	N	H	-	CH ₂ CH(2-propyl)NH ₂	H	H ₂ O (1:1)
55	B6b	8	CH	2-Br	-	**	H	
56	B1c	8	CH	2-Br	-	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:3);H ₂ O(1:3)
57	B6b	8	CH	2-CH ₃	-	**	H	

Co. No.	Ex. No.	*	a	R ^a	G	R ^b	R ^c	Physical data
58	B1c	8	CH	2-CH ₃	-	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:4);H ₂ O(1:1)
59	B6a	2	CH	H	CH ₂	**	H	
60	B1c	2	CH	H	CH ₂	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:4);H ₂ O(1:1)
61	B6a	2	CH	3-OCH	CH ₂	**	H	
62	B1c	2	CH	3-OCH	CH ₂	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:4);H ₂ O(1:1)
63	B7	2	CH	3-OH	CH ₂	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:4);H ₂ O(1:1)
64	B1a	8	N	3-Cl	-	H	H	
65	B4	8	N	3-Cl	-	**	H	
66	B1c	8	N	3-Cl	-	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:3);H ₂ O(1:1)
67	B2	8	N	H	-	CH ₂ CH ₂ NH ₂	H	HCl(1:3);H ₂ O(1:3)
68	B1a	8	N	2-Cl	-	H	H	
69	B4	8	N	2-Cl	-	**	H	
70 ⁽¹⁰⁾	B1c	8	N	2-Cl	-	CH ₂ CH(2-propyl)NH ₂	H	HCl(1:3);H ₂ O(1:1)
139	B1c	5	N	3-Cl	-	CH ₂ CH ₂ NH ₂	CH ₃	HCl(1:3);H ₂ O(1:2)
140	B1d	5	N	H	-	CH ₂ CH(2-propyl)NH ₂	CH ₃	
141	B1c	5	N	2-Cl	-	CH ₂ CH ₂ NH ₂	CH ₃	HCl(1:3);H ₂ O(1:3)
142	B1c	5	N	2-Cl	-	CH ₂ CH(2-propyl)NH ₂	CH ₃	

- * position bicyclic heterocycle
- ** CH₂CH(2-propyl)NH(C=O)OC(CH₃)₃

Table 8




5

Comp. No	Ex. No.	a	b	R ^a	R ^b	G	R ^c	Physical data
71		N	N	H	H	-	H	
72		S	N	-	H	-	H	
73	B1a	O	N	-	H	-	H	HBr(1:2);H ₂ O(2:1)

Comp. No	Ex. No.	a	b	R ^a	R ^b	G	R ^c	Physical data
74		N	N	H	H	CH ₂	H	
75		N	N	H	H	CH ₂	CH ₂ CH ₂ NH ₂	H ₂ O (1:1)
76		O	CH	-	H	CH ₂	H	
77		N	N	CH ₃	H	CH ₂	H	
78	B1c	N	N	CH ₃	H	CH ₂	CH ₂ CH ₂ NH ₂	
79		S	CH	-	H	CH ₂	H	
80	B1a	S	N	-	H	CH ₂	H	HCl(1:2);H ₂ O(1:1)
81	B2	N	N	H	H	-	CH ₂ CH ₂ NH ₂	HCl(1:4)
82	B1a	N	N	H	OCH ₃	CH ₂	H	
83	B1b	S	N	-	H	-	*	H ₂ O (1:1)
84	B1c	S	N	-	H	-	CH ₂ CH ₂ NH ₂	HCl(1:3);H ₂ O(1:1)
85	B1b	N	N	CH ₃	H	CH ₂	*	
86	B1b	O	N	-	H	-	*	
87	B1c	O	N	-	H	-	CH ₂ CH ₂ NH ₂	


* CH₂CH₂NH(C=O)OC(CH₃)₃

Table 9





Comp. No.	Ex. No.	R ^a	Physical data
102	B1a	H	HCl (1:3)
103	B5	CH ₂ CH(2-propyl)NH ₂	H ₂ O (1:1)

Table 10




Rnr	Comp. No.	Ex. No.	R ^b	R ^c	G-R ^a	Physical data
	93		H	H	-CH ₂ -imidazo[1,2-b]pyridine	
	101		CH ₂ CH ₂ NH ₂	H	-CH ₂ -imidazo[1,2-b]pyridine	
	94		CH ₂ CH ₂ NH(C=O)O CH ₂ CH ₃	H	-CH ₂ -thiophen[3,2-b]indole	
	95		CH ₂ CH ₂ NH ₂	H	-CH ₂ -thiophen[3,2-b]indole	
	96	B1a	H	H	-CH ₂ -imidazo[1,2-b]pyridine-C(F ₃) ₂	
	97	B2	CH ₂ CH ₂ NH ₂	H	-CH ₂ -imidazo[1,2-b]pyridine-C(F ₃) ₂	HCl(1:3);H ₂ O(1:1)
	98	B1a	H	H	-CH ₂ -imidazo[1,2-b]pyridine	
	99	B1c	CH ₂ CH(2-propyl)NH ₂	H	-CH ₂ -imidazo[1,2-b]pyridine	HCl(1:3);H ₂ O(1:3)
	108	B5	CH ₂ CH(2-propyl)NH ₂	H	-CH ₂ -imidazo[1,2-b]pyridine	

Rnr	Comp. No.	Ex. No.	R ^b	R ^c	G-R ^a	Physical data
	114		*	H		
	143	B6	CH ₂ CH(2-propyl)NH ₂	CH ₃		

* CH₂CH(2-propyl)NH(C=O)OC(CH₃)₃

Table 11




Co No.	Ex. No.	a-a1-a2-a3	*	R ^a	R ^c	R ^b	G	Physical data
144	B1c	CH=N-CH=C	8	H	-	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:3); H ₂ O(1:4)
145	B1c	CH=C-N=C	8	H	H	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:3); H ₂ O(1:2)
146	B1c	CH=C-C=N	8	-	H	CH ₂ CH(2-propyl)NH ₂	CH ₂	HCl(1:3); H ₂ O(1:2)
147	B2	CH=C-CH=C	8	CH ₃	Cl	H	CH ₂	
148	B3	CH=N-CH=C	8	H	-	CH ₂ CH ₂ NH ₂	CHOC ₂ H ₅	
149	B2	CH=C-CH=N	8	-	H	H	CH ₂	HCl(1:2); H ₂ O(1:1)
150	B1c	CH=C-CH=C	7	CH ₃	Cl	CH ₂ CH ₂ NH ₂	CH ₂	HCl(1:4); H ₂ O(1:2)
151	B3	CH=N-CH=C	8	H	-	CH ₂ CH ₂ NH ₂	CH ₂	

Co No.	Ex. No.	a-a1-a2-a3	*	R ^a	R ^c	R ^b	G	Physical data
152	B2	CH=N-CH=C	8	H	-	H	CH ₂	HCl(1:4); H ₂ O(1:2)
153	B3	CH=C-CH=N	8	-	H	CH ₂ CH ₂ NH ₂	CHOC ₂ H ₅	

• position bicyclic heterocycle


Table 12

Co No.	Ex. No.	R ^a	R ^b	Physical data
154	B1c	H	3-propylamine	
155	B1b	H	(H ₃ C) ₃ C-O-C(=O)-NH-CH ₂ CH ₂ CH ₂ NH ₂	HCl(1:3);H ₂ O(1:1)
156	B1e	H	H ₂ N-CH ₂ -NH-CH ₂ -CH ₂ -	
157	B7c	H	(H ₃ C) ₃ C-O-C(=O)-HN-Cyclohexyl	trans
158	B7c	H	H ₃ C-C(=O)-NH-CH ₂ -CH ₂ -	
159	B9a	H	2-ethylamine	
160	B1c	H	3-propylmethylamine	
161	B1c	H	H ₂ N-CH ₂ -NH-Cyclohexyl	cis;HCl(1:3);H ₂ O(1:1)
162	B1c	H	H ₂ N-CH ₂ -NH-CH(CH ₃)-CH ₂ -	HCl(1:4);H ₂ O(1:1)
163	B4	H	3-isobutylamine	
164	B1c	H	2-ethylmethylamine	HCl(1:2)



Co No.	Ex. No.	R ^a	R ^b	Physical data
165	B1a	H		trans;H ₂ O(1:1)
166	B9a	CH ₃	2-ethylamine 	
167	B9b	H		cis
168	B7c	H		cis
169	B3	H		HCl(1:3);H ₂ O(1:2)
170	B10	H		
171	B10	H		H ₂ O(1:1)
172	B1c	H		HCl(1:4);H ₂ O(1:2)
173	B9c	H		HCl(1:3)H ₂ O(1:2)
174	B1c	H		
175	B7c	H		cis
176	B12	H		

Table 13



Co No.	Ex. No.	G	L	a.	R _a	Physical data
177	B1d	2-ethylamine		CH	H	HCl(1:3);H ₂ O (1:3)
178	B1c	2-ethylamine		N	H	HCl(1:4);H ₂ O (1:4)
179	B1c	2-ethylamine		CH	CH ₃	H ₂ O(1:1)
180	B1b			CH	H	
181	B1c			CH	H	HCl(1:3);H ₂ O (1:2)
182	B1c	2-ethylamine		CH	H	HCl(1:3);H ₂ O (1:2)
183	B1c	2-ethylamine		CH	H	
184	B1c	2-ethylamine		CH	H	HCl(1:4);H ₂ O (1:1)
185	B1d	2-ethylamine		CH	H	C ₂ H ₂ O ₄ (2:7)

Table 14: Physical data

Comp. No.	C		H		N		melting point
	Theor.	Exp.	Theor.	Exp.	Theor.	Exp.	
1	61.40	60.70	5.85	6.04	16.27	15.54	
3	51.08	51.16	6.07	6.35	14.89	14.17	
4	73.92	73.29	6.49	6.52	19.59	19.38	206°C
6	73.27	73.12	7.74	7.73	18.99	18.77	135°C
7	73.27	71.85	7.74	7.80	18.99	18.61	188°C
8	70.40	69.73	7.88	7.40	18.24	17.56	80°C
9							> 250°C
10	73.27	72.82	7.74	7.58	18.99	18.63	172°C
11							190°C
13	67.98	66.43	6.97	6.79	17.62	17.02	164°C
15	71.16	70.66	7.68	7.58	17.78	17.81	210°C
19	51.45	51.64	6.97	6.89	16.15	15.96	240°C
22	68.47	68.04	7.45	7.52	20.70	20.55	206°C
23	73.92	71.70	6.49	6.53	19.59	19.92	140°C
24	71.97	69.89	7.05	7.10	20.98	20.07	196°C
89	51.46	53.22	6.94	7.11	15.00	15.14	24°C
91	70.85	69.82	8.07	8.29	17.71	17.48	180°C
92	72.43	71.51	7.29	7.30	20.27	20.10	176°C
104	72.87	70.26	7.53	7.27	19.61	18.73	88°C
105	72.87	71.37	7.53	7.39	19.61	19.39	135°C
106	65.69	66.19	7.96	7.62	19.86	19.71	110°C
26	69.02	69.16	7.99	7.68	16.65	16.79	140°C
27	71.57	70.60	7.87	7.80	17.27	17.14	166°C
29	67.86	67.64	8.08	7.79	15.32	15.15	100°C
31	70.16	68.97	7.98	7.97	15.84	15.56	110°C
32	70.16	69.35	7.98	8.34	15.84	14.73	98°C
33	71.79	70.72	6.78	7.17	17.44	16.69	145°C
37							215°C
39							209°C
40	68.80	66.01	6.78	6.60	24.42	23.31	138°C
42	70.40	69.14	7.50	7.50	22.10	21.68	180°C
43	74.36	73.02	6.78	6.65	18.85	18.41	155°C
44	72.26	71.53	7.03	7.26	16.85	16.40	186°C
45	68.80	66.74	6.78	6.64	24.42	23.77	178°C
100	71.57	71.16	7.87	7.93	17.27	17.44	202°C
107	71.57	69.77	7.87	7.85	17.27	16.40	78°C

Comp. No.	C		H		N		melting point
	Theor.	Exp.	Theor.	Exp.	Theor.	Exp.	
46							230°C
47							230°C
48	72.59	71.54	7.25	7.13	20.16	19.91	205°C
49	69.30	70.08	8.50	8.37	18.65	18.93	140°C
51	72.19	70.66	8.39	8.43	19.43	18.79	120°C
53	69.25	68.88	8.14	8.28	22.61	22.23	
54	66.49	66.30	8.26	7.77	21.71	21.53	144°C
56	46.27	47.19	6.57	6.44	12.45	12.16	> 250°C
58							210°C
60							212°C
62	52.51	53.38	7.24	7.63	13.12	12.37	240°C
63	51.76	52.74	7.08	7.32	13.41	12.93	240°C
66	50.43	50.60	6.60	6.58	16.47	16.28	> 250°C
67	47.62	46.73	6.90	6.83	17.67	17.19	230°C
70							238°C
80							210°C
81	48.38	47.77	5.61	5.61			
82	67.00	66.51	6.43	6.29	22.32	22.12	
83	61.15	62.11	6.71	6.60	16.46	16.88	
84	48.51	48.46	5.62	5.35	16.16	16.03	
87	67.00	66.42	6.43	6.55	22.32	21.80	
103	68.78	68.77	8.31	8.23	19.25	18.78	88°C
96	58.73	58.59	5.16	5.03	22.83	22.40	144°C
97							210°C
99	53.51	52.63	7.15	7.02	13.87	13.24	200°C
108	70.08	68.99	7.92	8.10	22.00	21.65	160°C
116							203°C
117							218°C
141							225°C
177							> 260°C
139							190°C
118							48°C
144							220°C
143	70.55	66.03	8.11	8.14	21.33	18.98	
119							145°C
121							185°C
140							172°C
120							210°C

-81-

Comp. No.	C		H		N		melting point
	Theor.	Exp.	Theor.	Exp.	Theor.	Exp.	
142							98°C
122							245°C
154							90°C
145							190°C
123							194°C
124							150°C
146							240°C
125							74°C
178							160°C
150							>250°C
126							90°C
127							200°C
128							210°C
157							185°C
159							140°C
151							212°C
160	73.02	72.95	6.71	6.70	20.27	20.35	
129							170°C
130							150°C
131							>250°C
152							230°C
153							169°C
131							120°C
161							206°C
132							160°C
133							210°C
134							81°C
162							210°C
147							>250°C
163							168°C
179							116°C
135	62.16	62.10	6.12	6.06	15.76	15.71	
164							146°C
136							188°C
165							112°C
166							114°C
149							210°C
180							247°C

Comp. No.	C		H		N		melting point
	Theor.	Exp.	Theor.	Exp.	Theor.	Exp.	
167							167°C
181							235°C
182							>250°C
184	47.75	47.58	6.01	6.37	17.72	17.00	
169							180°C
170							73°C
171							72°C
172							178°C
173							190°C
137							196°C
175							228°C
176							168°C
185							158°C

C. Pharmacological example

Example C1 : In vitro screening for activity against Respiratory Syncytial Virus.

The percent protection against cytopathology caused by viruses (antiviral activity or 5 IC_{50}) achieved by tested compounds and their cytotoxicity (CC_{50}) were both calculated from dose-response curves. The selectivity of the antiviral effect is represented by the selectivity index (SI), calculated by dividing the CC_{50} (cytotoxic dose for 50% of the cells) by the IC_{50} (antiviral activity for 50 % of the cells).

10 Automated tetrazolium-based colorimetric assays were used for determination of IC_{50} and CC_{50} of test compounds. Flat-bottom, 96-well plastic microtiter trays were filled with 180 μ l of Eagle's Basal Medium, supplemented with 5 % FCS (0% for FLU) and 20 mM Hepes buffer. Subsequently, stock solutions (7.8 x final test concentration) of compounds were added in 45 μ l volumes to a series of triplicate wells so as to allow 15 simultaneous evaluation of their effects on virus- and mock-infected cells. Five five-fold dilutions were made directly in the microtiter trays using a robot system. Untreated virus controls, and HeLa cell controls were included in each test. Approximately 100 $TCID_{50}$ of Respiratory Syncytial Virus was added to two of the three rows in a volume of 50 μ l. The same volume of medium was added to the third row to measure the 20 cytotoxicity of the compounds at the same concentrations as those used to measure the antiviral activity. After two hours of incubation, a suspension (4×10^5 cells/ml) of HeLa cells was added to all wells in a volume of 50 μ l. The cultures were incubated at

37°C in a 5% CO₂ atmosphere. Seven days after infection the cytotoxicity and the antiviral activity was examined spectrophotometrically. To each well of the microtiter tray, 25 µl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added. The trays were further incubated at 37°C for 2 hours, after which 5 the medium was removed from each cup. Solubilization of the formazan crystals was achieved by adding 100 µl 2-propanol. Complete dissolution of the formazan crystals were obtained after the trays have been placed on a plate shaker for 10 min. Finally, the absorbances were read in an eight-channel computer-controlled photometer (Multiskan 10 MCC, Flow Laboratories) at two wavelengths (540 and 690 nm). The absorbance measured at 690 nm was automatically subtracted from the absorbance at 540 nm, so as to eliminate the effects of non-specific absorption.


Particular IC₅₀, CC₅₀ and SI values are listed in Table 15 hereinbelow.

Table 15

Co. No.	IC ₅₀ (µM)	CC ₅₀ (µM)	SI
42	0.0004	>10.05	>25119
31	0.0008	12.68	15849
56	0.0016	12.71	7943
145	0.00631	25.12	3981
6	0.0126	10.00	794
156	0.01259	19.95	1585
131	0.0316	19.94	631
53	0.1259	>9.95	>79
29	0.3162	10.12	32
148	1	25	25
97	1.5849	>99.85	>63

Claims

1. A compound of formula



5 a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein

-a¹=a²-a³=a⁴- represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);


-N=CH-CH=CH- (a-2);

-CH=N-CH=CH- (a-3);

10 -CH=CH-N=CH- (a-4); or


-CH=CH-CH=N- (a-5);

15 wherein each hydrogen atom in the radicals (a-1), (a-2), (a-3), (a-4) and (a-5) may optionally be replaced by halo, C₁₋₆alkyl, nitro, amino, hydroxy, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, carboxyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl, or a radical of formula



wherein =Z is =O, =CH-C(=O)-NR^{5a}R^{5b}, =CH₂, =CH-C₁₋₆alkyl, =N-OH or =N-O-C₁₋₆alkyl;

20 Q is a radical of formula



wherein Alk is C₁₋₆alkanediyl;

Y¹ is a bivalent radical of formula -NR²- or -CH(NR²R⁴)-;

25 X¹ is NR⁴, S, S(=O), S(=O)₂, O, CH₂, C(=O), C(=CH₂), CH(OH), CH(CH₃), CH(OCH₃), CH(SCH₃), CH(NR^{5a}R^{5b}), CH₂-NR⁴ or NR⁴-CH₂;

X^2 is a direct bond, CH_2 , $C(=O)$, NR^4 , $C_{1-4}alkyl-NR^4$, $NR^4-C_{1-4}alkyl$;

t is 2, 3, 4 or 5;

u is 1, 2, 3, 4 or 5;

v is 2 or 3; and


5 whereby each hydrogen atom in Alk and the carbocycles and the heterocycles defined in radicals (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8) may optionally be replaced by R^3 ; with the proviso that when R^3 is hydroxy or $C_{1-6}alkyloxy$, then R^3 can not replace a hydrogen atom in the α position relative to a nitrogen atom;

G is a direct bond or $C_{1-10}alkanediyi$ optionally substituted with one, two or three


10 substituents selected from hydroxy, $C_{1-6}alkyloxy$, $arylC_{1-6}alkyloxy$, $C_{1-6}alkylthio$, $arylC_{1-6}alkylthio$, arylcarbonyl, $HO(-CH_2-CH_2-O)_n-$, $C_{1-6}alkyloxy(-CH_2-CH_2-O)_n-$, $arylC_{1-6}alkyloxy(-CH_2-CH_2-O)_n-$, amino, mono- or di($C_{1-6}alkyl$)amino, $C_{1-6}alkyloxycarbonylamino$ and aryl;

R^1 is a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, benzofuranyl,


15 benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula




(c-1)




(c-2)




(c-3)




(c-4)




(c-5)



(c-6)



(c-7)



(c-8)

and said bicyclic heterocycles may optionally be substituted in either of the two cycles

20 with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, $C_{1-6}alkyl$, $C_{1-6}alkyloxy$, $C_{1-6}alkylthio$, $C_{1-6}alkyloxy-C_{1-6}alkyl$, aryl, $arylC_{1-6}alkyl$, $arylC_{1-6}alkyloxy$, hydroxy $C_{1-6}alkyl$, mono- or di($C_{1-6}alkyl$)-amino, mono- or di($C_{1-6}alkyl$)amino $C_{1-6}alkyl$, polyhalo $C_{1-6}alkyl$, $C_{1-6}alkylcarbonylamino$, $C_{1-6}alkyl-SO_2-NR^{5c}-$, aryl- $SO_2-NR^{5c}-$, $C_{1-6}alkyloxycarbonyl$, $-C(=O)-NR^{5c}R^{5d}$, $HO(-CH_2-CH_2-O)_n-$, halo(- $CH_2-CH_2-O)_n-$, $C_{1-6}alkyloxy(-CH_2-CH_2-O)_n-$, $arylC_{1-6}alkyloxy(-CH_2-CH_2-O)_n-$ and mono- or di($C_{1-6}alkyl$)amino(- $CH_2-CH_2-O)_n-$;

25 each n independently is 1, 2, 3 or 4;

each m independently is 1 or 2;

each p independently is 1 or 2;

each R² independently is hydrogen, formyl, C₁₋₆alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C₃₋₇cycloalkyl substituted with N(R⁶)₂, or C₁₋₁₀alkyl substituted with N(R⁶)₂ and optionally with a second, third or fourth

5 substituent selected from amino, hydroxy, C₃₋₇cycloalkyl, C₂₋₅alkanediyl, piperidinyl, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, aryl and aryloxy;

R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl or arylC₁₋₆alkyloxy;

R⁴ is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;

R^{5a}, R^{5b}, R^{5c} and R^{5d} each independently are hydrogen or C₁₋₆alkyl; or

10 R^{5a} and R^{5b}, or R^{5c} and R^{5d} taken together form a bivalent radical of formula -(CH₂)_s- wherein s is 4 or 5;

R⁶ is hydrogen, C₁₋₄alkyl, formyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl or C₁₋₆alkyloxycarbonyl;

aryl is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents

15 selected from halo, hydroxy, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, polyhaloC₁₋₆alkyl, and C₁₋₆alkyloxy;

Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.

2. A compound according to claim 1 wherein -a¹=a²-a³=a⁴- is a radical of formula (a-1), (a-2) or (a-3).

20 3. A compound according to claim 1 or 2 wherein Q is a radical of formula (b-5) wherein v is 2 and Y¹ is -NR²-.

25 4. A compound according to anyone of claims 1 to 3 wherein R² is C₁₋₁₀alkyl substituted with NHR⁶.

5. A compound according to anyone of claims 1 to 4 wherein G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one, two or three substituents selected

30 from hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, HO(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n-,

35 6. A compound according to claim 1 wherein the compound is selected from (±)-N-[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-[1-(8-quinolinyl)ethyl]-1H-benzimidazol-2-amine monohydrate; (±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-bromo-5,6,7,8-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-amine trihydrochloride trihydrate; (±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-4-methyl-1H-benzimidazol-

2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(1-methyl-1*H*-benzimidazol-4-yl)methyl]-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(ethoxy-8-quinolinylmethyl)-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-(5,6,7,8-tetrahydro-5-quinoxaliny)-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride trihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride monohydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(8-quinolinylmethyl)-1*H*-imidazo[4,5-c]pyridin-2-amine trihydrochloride dihydrate; *N*-[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-amine; *N*-[1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-yl]-1,3-propanediamine trihydrochloride monohydrate; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine trihydrochloride dihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(8-quinolinylmethyl)-1*H*-imidazo[4,5-b]pyridine-2-amine trihydrochloride dihydrate; (\pm)-*N*-[1-[1-(aminomethyl)-2-methylpropyl]-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine trihydrochloride trihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(1-isoquinolinylmethyl)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; *N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(5,6,7,8-tetrahydro-5-quinoxaliny)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-(8-quinolinylmethyl)-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-4-methyl-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(5,6,7,8-tetrahydro-2,3-dimethyl-5-quinoxaliny)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-1*H*-benzimidazol-2-amine trihydrochloride monohydrate; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-4-methyl-1*H*-benzimidazol-2-amine trihydrochloride dihydrate; (\pm)-*N*-[1-(2-


5 aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-4-methyl-1*H*-benzimidazol-2-amine monohydrate; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-c]pyridin-2-amine trihydrochloride tetrahydrate; (\pm)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-b]pyridin-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-[(1-methyl-1*H*-benzimidazol-4-yl)methyl]-1*H*-benzimidazol-2-amine; (\pm)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-4-methyl-1*H*-benzimidazol-2-amine; a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or 10 stereochemically isomeric form thereof.

7. A compound according to any one of claims 1 to 6 for use as a medicine.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 6.


9. A process of preparing a composition as claimed in claim 8, characterized in that, a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as described in any one of claims 1 to 6.

10. An intermediate of formula




25 with R^1 , G and $-a^1 = a^2 - a^3 = a^4$ defined as in claim 1, P being a protective group, and Q_1 being defined as Q according to claim 1 but being devoided of the R^2 or R^6 substituent.

11. An intermediate of formula



with R^1 , G and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, and $(O=)Q_3$ being a carbonyl derivative of Q , said Q being defined according to claim 1, provided that it is devoided of the NR^2R^4 or NR^2 substituent.


5 12. An intermediate of formula



with R^1 , Q and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, and $(O=)G_2$ being a carbonyl derivative of G , said G being defined according to claim 1.


10 13. A process of preparing a compound as claimed in claim 1, characterized by,

a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III)



15 with R^1 , G , Q and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, and W_1 being a suitable leaving group, in the presence of a suitable base and in a suitable reaction-inert solvent;


b) deprotecting an intermediate of formula (IV)



-90-

with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, $H-Q_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen, and P being a protective group;


5 c) deprotecting and reducing an intermediate of formula (IV-a)



with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, $H-Q_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen, $Q_{1a}(CH=CH)$ being defined as Q_1 provided that Q_1 comprises an unsaturated bond, and P being a protective group;

10 10


d) deprotecting an intermediate of formula (V)



with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and H_2N-Q_2 being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen;

15 15


e) deprotecting an intermediate of formula (VI)



with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and H_2N-Q_2 being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen, and P being a protective group;


20 20

f) deprotecting an intermediate of formula (VII) or (VIII)




with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, $H-Q_1 \cdot (OH)$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen and provided that Q comprises a hydroxy moiety, $H_2N-Q_2 \cdot (OH)$ being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen and provided that Q comprises a hydroxy moiety, and P being a protective group;

5 g) amination of an intermediate of formula (IX)




10 with R^1 , G , and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and H_2N-Q_3H being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen, and the carbon adjacent to the nitrogen carrying the R^6 , or R^2 and R^4 substituents contains at least one hydrogen, in the presence of a suitable amination reagent;

15 h) reducing an intermediate of formula (X)



with R^1 , G, and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and $H_2N-CH_2-Q_4$ being defined as Q according to claim 1 provided that Q comprises a $-CH_2-NH_2$ moiety, in the presence of a suitable reducing agent;


i) reducing an intermediate of formula (X-a)



5


with G, and $-a^1=a^2-a^3=a^4$ defined as in claim 1, $H_2N-CH_2-Q_4$ being defined as Q according to claim 1 provided that Q comprises a $-CH_2-NH_2$ moiety, and R^1 being defined as R^1 according to claim 1 provided that it comprises at least one substituent, in the presence of a suitable reducing agent and suitable solvent;

10 j) amination of an intermediate of formula (XI)




with R^1 , G, and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and $H_2N-CH_2-CHOH-CH_2-Q_4$ being defined as Q according to claim 1 provided that Q comprises a $CH_2-CHOH-CH_2-NH_2$ moiety, in the presence of a suitable amination reagent;

15 k) reacting an intermediate of formula (XII) with formic acid, formamide and ammonia



with R^1 , G, and $-a^1=a^2-a^3=a^4$ defined as in claim 1, and $H-C(=O)-Q_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is formyl;


20 l) amination of an intermediate of formula (XIII) by reaction with an intermediate of formula (XIV)



with R^1 , G , and $-a^1 = a^2 - a^3 = a^4$ defined as in claim 1, and R^{2a} -NH-HQ₅ being defined as Q according to claim 1 provided that R^2 is other than hydrogen and is represented by R^{2a} , R^4 is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the R^2 and R^4 substituents, carries also at least one hydrogen atom, in the presence of a suitable reducing agent;

5

m) reducing an intermediate of formula (XV)




with R^1 , G , and $-a^1 = a^2 - a^3 = a^4$ - defined as in claim 1, and


10

$(R^6)_2N-[(C_{1-9}alkyl)CH_2OH]-NH-HQ_5$ being defined as Q according to claim 1 provided that R^2 is other than hydrogen and is represented by $C_{1-10}alkyl$ substituted with $N(R_6)_2$ and with hydroxy, and the carbon atom carrying the hydroxy, carries also two hydrogen atoms, and provided that R^4 is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the R^2 and R^4 substituents, carries also at least one hydrogen atom, with a suitable reducing agent;

15


n) deprotecting an intermediate of formula (XVI), (XVI-a) or (XVI-b)






with G, and $-a^1 = a^2 - a^3 = a^4$ defined as in claim 1, and H-Q₁ being defined as Q according to claim 1 provided that R² or at least one R⁶ substituent is hydrogen, and R^{1a}-(A-O-H)_w, R^{1a'}-(A-O-H)₂ and R^{1a''}-(A-O-H)₃ being defined as R¹ according to claim 1 provided that R¹ is substituted with hydroxy, hydroxyC₁₋₆alkyl, or HO(-CH₂-CH₂-O)_n-, with w being an integer from 1 to 4 and P or P₁ being a suitable protecting group, with a suitable acid.

o) amination of an intermediate of formula (XVII)



with R^1 , G , $-a^1 = a^2 - a^3 = a^4$, Alk , $X^1 R^2$ and R^4 defined as in claim 1, in the presence of a suitable amination agent;


p) amination of an intermediate of formula (XIX)



15 with R¹, G, and -a¹=a²-a³=a⁴ defined as in claim 1, and Q₆N-CH₂-C₁₋₃alkyl-NR⁴


being defined as Q according to claim 1 provided that in the definition of Q, X² is C₂₋₄alkyl-NR⁴, in the presence of a suitable amination agent;

q) deprotecting an intermediate of formula (XXI)



5 with R¹, Q, and -a¹=a²-a³=a⁴- defined as in claim 1, and HO-G₁ being defined as G according to claim 1 provided that G is substituted with hydroxy or HO-(CH₂CH₂O-)_n;

r) reducing an intermediate of formula (XXII)



10 with R¹, Q, and -a¹=a²-a³=a⁴- defined as in claim 1, and H-G₂-OH being defined as G according to claim 1 provided that G is substituted with hydroxy and the carbon atom carrying the hydroxy substituent carries also at least one hydrogen, in the presence of a suitable reducing agent.

15 and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, metal complexes, quaternary amines or N-oxide forms thereof.

20 14. A product containing (a) a compound as defined in claim 1, and (b) another antiviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment or the prevention of viral infections.

-96-

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 1, and (b) another antiviral compound.

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/EP 00/05677

A. CLASSIFICATION OF SUBJECT MATTER						
IPC 7	C07D401/14	A61K31/4709	A61K31/4375	A61K31/437	A61K31/498	
	A61K31/4409	A61K31/436	A61P11/00	A61P31/12	C07D471/04	
	C07D417/14	C07D413/14	C07D409/14	C07D401/06	C07D491/056	

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 01697 A (JANSSEN PHARMACEUTICA NV) 6 February 1992 (1992-02-06) page 21, line 9 - line 12; claim 1 -----	1,7
P, X	WO 99 44596 A (JANSSEN PHARMACEUTICA) 10 September 1999 (1999-09-10) page 11, line 18 - line 19; claim 1 -----	1,7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

13 October 2000

Date of mailing of the international search report

27/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 00/05677

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 // (C07D471/04, 221:00, 221:00), (C07D471/04, 235:00, 221:00),
 (C07D491/056, 319:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 October 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Alfarro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 00 05677

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 to 15, relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formula I where Q is a 1-R₂-piperidyl-4-amino or amino(cyclo)alkylamino group and their intermediates as described in the examples of tables 3 to 13.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05677

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9201697	A 06-02-1992	AT	188477 T	15-01-2000
		AU	646280 B	17-02-1994
		AU	8209391 A	18-02-1992
		CA	2086546 A	20-01-1992
		CN	1058216 A, B	29-01-1992
		CS	9102239 A	19-02-1992
		DE	69131895 D	10-02-2000
		DE	69131895 T	20-07-2000
		EP	0539420 A	05-05-1993
		ES	2142802 T	01-05-2000
		FI	930199 A	18-01-1993
		GR	3032999 T	31-07-2000
		HU	64066 A	29-11-1993
		IL	98865 A	27-11-1995
		KR	206723 B	01-07-1999
		MX	9100307 A	28-02-1992
		NO	304791 B	15-02-1999
		NZ	238863 A	26-03-1993
		PL	170580 B	31-01-1997
		PT	98366 A, B	29-05-1992
		RU	2067978 C	20-10-1996
		US	5360807 A	01-11-1994
		ZA	9105654 A	31-03-1993
WO 9944596	A 10-09-1999	AU	3408999 A	20-09-1999

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00615 A1(51) International Patent Classification⁷: C07D 401/14, A61K 31/4709, 31/4375, 31/437, 31/498, 31/4409, 31/436, A61P 11/00, 31/12, C07D 471/04, 417/14, 413/14, 409/14, 401/06, 491/056

(21) International Application Number: PCT/EP00/05677

(22) International Filing Date: 20 June 2000 (20.06.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
99202089.1 28 June 1999 (28.06.1999) EP(72) Inventors; and
(75) Inventors/Applicants (for US only): JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LACRAMPE, Jean, Fernand, Armand [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). GUILLEMONT, Jérôme, Emile, Georges [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). VENET, Marc, Gaston [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). ANDRIES, Koenraad, Jozef, Lodewijk, Marcel [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department - 3547, Turnhoutseweg 30, B-2340 Beerse (BE).

[Continued on next page]

(54) Title: RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS



(57) Abstract: The present invention concerns compounds of formula (I), prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein $a^1-a^2-a^3=a^4$, represents a radical of formula -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein each hydrogen atom may optionally be substituted; Q is a radical of formulae (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), wherein Alk is C₁₋₆alkanediyl; Y¹ is a bivalent radical of formula -NR²- or -CH(NR²R⁴)-; X¹ is NR⁴, S, S(=O), S(=O)₂, O, CH₂, C(=O), CH(=CH₂), CH(OH), CH(CH₃), CH(OCH₃), CH(SCH₃), CH(NR^{5a}R^{5b}), CH₂-NR⁴ or NR⁴-CH₂; X² is a direct bond, CH₂, C(=O), NR⁴, C₁₋₆alkyl-NR⁴, NR⁴-C₁₋₆alkyl, t is 2 to 5; u is 1 to 5; v is 2 or 3; and whereby each hydrogen in Alk and in (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), may optionally be replaced by R³; provided that when R³ is hydroxy or C₁₋₆alkyloxy, then R³ cannot replace a hydrogen atom in the α position relative to a nitrogen atom; G is a direct bond or optionally substituted C₁₋₁₀alkanediyl; R¹ is an optionally substituted bicyclic heterocycle; R² is hydrogen, formyl, C₁₋₆alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C₃₋₇cycloalkyl or C₁₋₁₀alkyl substituted with N(R⁶)₂ and optionally with another substituent; R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl or arylC₁₋₆alkyloxy, R⁴ is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; R^{5a}, R^{5b}, R^{5c} and R^{5d} are hydrogen or C₁₋₆alkyl; or R^{5a} and R^{5b}, or R^{5c} and R^{5d} taken together from a bivalent radical of formula -(CH₂)₅-, wherein S is 4 or 5; R⁶ is hydrogen, C₁₋₄alkyl, formyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl or C₁₋₆alkyloxycarbonyl; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.

WO 01/00615 A1



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) **Date of publication of this corrected version:**

10 January 2002

(15) **Information about Correction:**

see PCT Gazette No. 02/2002 of 10 January 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.